user_id,prompt id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
edin,82,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
edin,17,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", cervical Bishop's score , placebo , antibiotic therapy ,0,
edin,75,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
edin,64,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
edin,79,2875419,No significant difference,"The proportions of patients achieving A1C <7% were also similar (44.1 and 47.8%, respectively, P = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C <6.5% (16.5 and 22.7%, respectively, P = 0.017).",  number of patients with A1C <7%  ,  glargine  ,  detemir  ,0,
edin,13,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
edin,88,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
edin,42,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
edin,51,524504,Significantly decreased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
edin,43,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,48,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
edin,77,3281242,Cannot tell based on the abstract,, time to make first quit attempt , placebo , varenicline ,0,
edin,77,3281242,Significantly increased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).", time to make first quit attempt , placebo , varenicline ,0,
edin,53,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
edin,60,524504,No significant difference,Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS,  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
edin,70,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,40,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,62,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
edin,95,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).,The maximum IVD dwell time was 1,023 hours (43 days) in the clinical replacement group, and this cannula was still working well on removal for completion of therapy.",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
edin,39,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
edin,55,524504,Cannot tell based on the abstract,,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,55,524504,No significant difference,Uterine Hyperstimulation	2 (2.5%)	1 (1.2%)	NS,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,3,3298351,Cannot tell based on the abstract,, venous ulcer healing , no treatment , compression therapy ,0,
edin,3,3298351,Significantly increased,The changes of ulceration area were statistically significant regardless of the type of compression therapy., venous ulcer healing , no treatment , compression therapy ,0,
edin,15,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
edin,26,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,26,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,30,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,30,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,46,2674549,Cannot tell based on the abstract,, serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,46,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.,During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,93,2944158,No significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,81,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
edin,34,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,27,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,27,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,90,2944158,Significantly increased,"This review included six trials (n = 3,455) and reported no clinically important or statistically significant difference in catheter-related bloodstream infection or phlebitis between IVDs that were routinely resited (at 48-96 hours) or resited on clinical indication, yet there were significantly lower costs in the group resited on clinical indication",  cost per patient  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,18,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", white blood cell count , placebo , antibiotic therapy ,0,
edin,23,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,16,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,0,
edin,56,524504,Cannot tell based on the abstract,,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,56,524504,No significant difference,Meconium stained AF	15 (18.8%)	7 (9.6%)	NS,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,54,524504,Significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).",  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
edin,67,1764008,No significant difference,Active phase of first Stage of labor (h)	2.49 ± 1.40	2.40 ± 1.55	NS,  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,37,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,85,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
edin,76,3281242,Cannot tell based on the abstract,,  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,76,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,41,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,89,2944158,Significantly increased,"The overall number of IVDs per patient was significantly less (P = 0.004) for those replaced on clinical indication (mean 1.5, SD 0.8, median 1, quartiles 1 and 2) than for those routinely replaced (mean 1.8, SD 1.1, median 1, quartiles 1 and 2)",  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,49,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
edin,58,524504,No significant difference,"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia,Neonatal resuscitation	9 (11.3%)	9 (10.8%)	NS",  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
edin,96,2858204,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,n the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",  frequency of healed index ucler after 1 year  ,  placebo  ,  HBOT   ,0,
edin,80,2875419,Significantly increased,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", number of patients with A1C <6.5% , glargine , detemir ,0,
edin,91,2944158,No significant difference,"Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.", IVD complications per person , staff inclination replacement , routine replacement ,0,
edin,44,2674549,Cannot tell based on the abstract,, serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,44,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients", serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,22,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,92,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., phlebitis , staff inclination replacement , routine replacement ,0,
edin,65,1764008,No significant difference,"Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS,Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,4,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , two-layer bandage , four-layer bandage ,0,
edin,74,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001)", continuous abstienence at week 12 , placebo , varenicline ,0,
edin,97,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
edin,86,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
edin,71,1764008,No significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,20,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,83,2875419,Significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001),Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (3,10,11). At present there is no clear explanation for the increased dose requirements for detemir",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
edin,2,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
edin,66,1764008,Cannot tell based on the abstract,,  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,66,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,29,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,29,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,45,2674549,Cannot tell based on the abstract,, serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,45,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.


Conclusion:", serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,73,1764008,No significant difference,"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.",  neonatal outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,10,3298351,Cannot tell based on the abstract,,  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,10,3298351,No significant difference,"Table I
Comparable characteristics of patients treated with Maxis compression stockings and ProGuide two-layer and Profore four-layer compression systems,Ulceration area [cm2] (x ± SD)	4.7 ±4.18	5.3 ±3.93	6.0 ±3.98	p > 0.05,In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system. The differences were statistically significant (p > 0.05).",  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,31,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,9,3298351,Significantly increased,"However, greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.",  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
edin,63,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
edin,38,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., symptoms of RA , methotrexate , golimumab and methotrexate ,0,
edin,84,2875419,Cannot tell based on the abstract,,  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,84,2875419,Significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,94,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)	RR 0.77 (0.21, 2.80), p = 0.75,There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,87,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., infections , staff inclination replacement , routine replacement ,0,
edin,7,3298351,No significant difference,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.",  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
edin,5,3298351,No significant difference,"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05",  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
edin,33,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
edin,28,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,28,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,19,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,12,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
edin,24,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , twice weekly single iron tablet , daily single iron tablets ,0,
edin,35,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,11,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
edin,72,1764008,No significant difference,"Women in both groups were similar in both obstetric and demographic characteristics,The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric intervention  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,36,3233526,No significant difference,"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks,,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).",  ferritin levels at week 38  ,  daily single iron tablets  ,  weekly supplements of two iron tablets  ,0,
edin,59,524504,No significant difference,The mean cord pH and the base deficit were comparable in the two groups.,  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,Cannot tell based on the abstract,,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,No significant difference,Perinatal death	0	1(1.2%)	NS,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,61,524504,No significant difference,Birth trauma 3	0	2 (2.5%)	NS,  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
edin,98,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
edin,32,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,69,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).,  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,14,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
edin,21,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
edin,8,3298351,Cannot tell based on the abstract,,  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,8,3298351,No significant difference,"greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week. The value of the same parameter in patients treated with the two-layer ProGuide compression system was 0.55 cm2/per week and of those treated with compression stockings 0.44 cm2/per week. Although the changes of ulceration area in each analysed group were statistically significant (p < 0.001), inter-group differences were not found (H = 4.45, p > 0.05).",  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,52,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05)", Caesarean section rate , misoprostol , dinoprostone ,0,
edin,78,2875419,No significant difference,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", improved A1C , glargine , detemir ,0,
edin,50,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
edin,68,1764008,Cannot tell based on the abstract,,  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,68,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,6,3298351,No significant difference,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
edin,25,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,25,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,47,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
edin,191,2517154,Cannot tell based on the abstract,,  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,191,2517154,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,159,2708184,Cannot tell based on the abstract,,  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,159,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,128,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,128,2871176,Invalid Prompt,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I don't have required information in abstract and I can't open the rest of article. I keep getting 404 page not found error 
edin,114,2871176,Cannot tell based on the abstract,,  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,114,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,211,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,211,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.,Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,179,2864284,Cannot tell based on the abstract,,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,179,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,132,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,132,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,134,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,134,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,103,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,143,2871176,Cannot tell based on the abstract,,  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,143,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,188,2517154,Cannot tell based on the abstract,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,188,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates. Routine pathology (FC) also showed no obvious differences between the two groups.",  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,163,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,163,2708184,No significant difference,"<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,189,2517154,Cannot tell based on the abstract,,  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,189,2517154,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,176,2864284,Cannot tell based on the abstract,,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,176,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,Cannot tell based on the abstract,,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,147,2871176,Cannot tell based on the abstract,,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,147,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002).,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,197,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25?1.69) and SU (37.9%; RR 1.45, 95% CI 1.22?1.73) (Table 2).",  Pain relief: Acupuncture  ,  Normal unit & Special unit  ,  Midwife-led unit  ,0,
edin,192,1852268,No significant difference,"In this study, ertapenem was as effective as piperacillin?tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin?tazobactam.,The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2?4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin?tazobactam were cured (95% confidence interval for the difference, adjusting for strata, ?4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillin?tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,204,4106715,Cannot tell based on the abstract,,  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,204,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20).",  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,164,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,164,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,121,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,121,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,1, I get 404 not found error when I want to see the whole article 
edin,160,2708184,Cannot tell based on the abstract,,  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,160,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,201,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,130,2871176,Cannot tell based on the abstract,,  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,130,2871176,Significantly decreased,"Although weight effects were modest, liraglutide produced more favourable weight effects compared with rosiglitazone, which produced substantial weight gain.",  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,135,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,135,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,208,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20)."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,169,2864284,Cannot tell based on the abstract,,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,169,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,137,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,137,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,209,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,209,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,120,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,120,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I got 404 Not Found error
edin,100,2871176,Cannot tell based on the abstract,,  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,100,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).",  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,154,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,154,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,205,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,205,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,156,2708184,Cannot tell based on the abstract,, Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,156,2708184,No significant difference,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,198,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
edin,112,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,112,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,212,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,177,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,155,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,155,2708184,No significant difference,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,184,2517154,Cannot tell based on the abstract,, Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,184,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,117,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,117,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,119,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,119,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,166,3001156,Cannot tell based on the abstract,, Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,166,3001156,Significantly increased,"Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital, and decreases were observed in care-seeking from unqualified providers in the intervention arm.", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,123,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,199,3187863,No significant difference,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth. An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively."," Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
edin,207,4106715,Significantly increased,"3?AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14?6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,99,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,99,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,206,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19?52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19?52) with high Ab levels ,0,
edin,172,2864284,Cannot tell based on the abstract,, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,172,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,107,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,107,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,195,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59?0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56?0.86) (Table 2).", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
edin,182,2517154,Cannot tell based on the abstract,, Nodules diameters , Placebo , Infliximab ,0,
edin,182,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
edin,202,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,202,4106715,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,168,2864284,Cannot tell based on the abstract,, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,168,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,190,2517154,Cannot tell based on the abstract,, Pain killers intake , Placebo , Infliximab ,0,
edin,190,2517154,Significantly increased,"The strong and significant placebo effect and the absence of an infliximab effect were consistently found for all pain estimations in this study, i.e. the five scorings by the clinician and the calculated total scores (i.e. dysmenorrhea, deep dyspareunia, chronic pain, pelvic tenderness, the sum of the 3 BB pain scores and the total BB score) and the pain recorded in the dairy by the patients (i.e. the 3 BB scores, the visual analog scales, the pain killer intake and both calculated total scores, i.e. with or without taking pain killer intake into account).", Pain killers intake , Placebo , Infliximab ,0,
edin,194,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65?0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59?0.89) (Table 2).", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
edin,186,2517154,Cannot tell based on the abstract,, Surgery duration , Placebo , Infliximab ,0,
edin,186,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
edin,136,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,136,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,116,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,116,2871176,Significantly decreased,"By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,173,2864284,Cannot tell based on the abstract,, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,173,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,167,3001156,Cannot tell based on the abstract,, Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,167,3001156,No significant difference,"At the time of the baseline household survey in January 2003, there was no significant difference between the intervention arm and the comparison arm of the study in the proportion of sick newborns who were taken outside the home for care from any qualified provider (including Kumudini Hospital), to the Kumudini Hospital specifically, or to an unqualified provider, most commonly an unlicensed ?village doctor?.", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,139,2871176,Cannot tell based on the abstract,, HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,139,2871176,No significant difference,"There were no significant differences between treatments for HOMA-IR.

Table 2", HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,213,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,110,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,110,2871176,Significantly increased,"The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,144,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,144,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,165,3001156,Cannot tell based on the abstract,, Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,165,3001156,No significant difference,Figure 2 demonstrates that there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8)., Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,109,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,109,2871176,Significantly decreased,"Rosiglitazone also was superior to placebo (P < 0.0001).,he greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,106,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,106,2871176,Significantly decreased,"Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,149,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,149,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,104,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,180,2864284,Cannot tell based on the abstract,, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,180,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,111,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,111,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).

FIGURE 4", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,187,2517154,Cannot tell based on the abstract,, Bleeding during surgery , Placebo , Infliximab ,0,
edin,187,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
edin,157,2708184,Cannot tell based on the abstract,, Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,157,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,122,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,122,2871176,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,126,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,126,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,158,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,158,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,125,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,183,2517154,Cannot tell based on the abstract,, Endometrial thickness , Placebo , Infliximab ,0,
edin,183,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3?18) and 7.8 (1.9?11) mm and for the placebo group 7.7 (1.8?23) and 8.2 (3?15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
edin,175,2864284,Cannot tell based on the abstract,, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,175,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,133,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,133,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,171,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,146,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,146,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,127,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,127,2871176,Significantly increased,"he percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,174,2864284,Cannot tell based on the abstract,, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,174,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,118,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,118,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,185,2517154,Cannot tell based on the abstract,, Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,185,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,142,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,142,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,162,2708184,Cannot tell based on the abstract,, Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,162,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,129,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,129,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,131,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,131,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,140,2871176,Cannot tell based on the abstract,, HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,140,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,203,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,203,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,170,2864284,Cannot tell based on the abstract,, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,170,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,150,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,150,2871176,No significant difference,"Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,124,2871176,Cannot tell based on the abstract,, Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,124,2871176,Significantly decreased,reatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5?2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone., Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,113,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,113,2871176,Significantly increased,"he estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,145,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,145,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,161,2708184,Cannot tell based on the abstract,, Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,161,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,102,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,102,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,108,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,108,2871176,No significant difference,"All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,181,2517154,Cannot tell based on the abstract,, Severity of pain , Placebo , Infliximab ,0,
edin,181,2517154,No significant difference,"Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). However, no effect of infliximab was observed for any of the outcome measures.", Severity of pain , Placebo , Infliximab ,0,
edin,141,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,141,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,153,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,153,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,210,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,210,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,196,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11?1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16?2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
edin,115,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,115,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,193,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
edin,200,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,200,2688140,No significant difference,"The overall mortality at 28 days was 37%. Mortality at 28 days was 33% in the control group and 40% in the decremental PEEP titration group (Table 2). Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,138,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,138,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,148,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,148,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002), Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,151,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,151,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,400,2690844,Cannot tell based on the abstract,, Complications after surgery , Midline incision , Transverse incision ,0,
edin,400,2690844,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30), Complications after surgery , Midline incision , Transverse incision ,0,
edin,442,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,442,2600646,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,376,3580134,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Awakening-free nights percentage improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,472,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,472,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,344,3580134,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ? 0.004) and with budesonide/formoterol 320/9 ?g compared with formoterol (p = 0.026) [figure 6]., Time to first COPD exacerbation , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,474,2847809,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03)., The primary arteriovenous fistula failures at two months , Placebo , Clopidogrel ,0,
edin,315,3580134,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,279,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Information recall , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,480,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,324,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours at end of treatment , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,406,2690844,Cannot tell based on the abstract,, Scar width , Midline incision , Transverse incision ,0,
edin,406,2690844,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001)., Scar width , Midline incision , Transverse incision ,0,
edin,481,2899760,Significantly increased,"Fusion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).", Fusion rate , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,224,1475568,Cannot tell based on the abstract,, Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,224,1475568,Significantly decreased,"The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,Patients enrolled in the control group received a general heart failure education pamphlet written at approximately the 7th grade level, and continued with usual care from their primary physician.", Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,374,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].,Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Sleep score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,319,3580134,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ? 0.012), Peak expiratory flow in the morning and evening  , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,440,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,440,2600646,No significant difference,"<td colspan=""8""><hr></td>", mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,268,2691927,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure., Need for opiates , Conventional open approach , Laparoscopic surgery ,0,
edin,286,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Quit attempt of 1 week or longer reported at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,309,2817867,Significantly increased,Sixty percent of patients suffered local recurrences after RFA compared to 7% after hepatic resection., Local recurrence rate through the study , Hepatic resection , Radiofrequency ablation ,0,
edin,241,3090298,Cannot tell based on the abstract,, Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,241,3090298,No significant difference,"Total root-mean square (RMS) HOAs, coma, trefoil, and spherical aberrations are compared in Figure 2. There were no significant differences between groups in any HOAs throughout the study (P ? 0.101), with all P values at 6 months ?0.63.", Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,216,1475568,Cannot tell based on the abstract,, Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,216,1475568,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.", Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,307,2817867,Cannot tell based on the abstract,, Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,307,2817867,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).", Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,432,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,432,3187863,Significantly increased,"There were statistically significant differences in augmentation (midwife-led unit versus normal unit RR 0.73, 95% CI 0.59?0.89; midwife-led unit versus special unit RR 0.69, 95% CI 0.56?0.86), in epidural analgesia (midwife-led unit versus normal unit RR 0.68, 95% CI 0.52?0.90; midwife-led unit versus special unit RR 0.64, 95% CI 0.47?0.86) and in acupuncture (midwife-led unit versus normal unit RR 1.45, 95% CI 1.25?1.69; midwife-led unit versus special unit RR 1.45, 95% CI 1.22?1.73).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,302,2817867,Cannot tell based on the abstract,, Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,302,2817867,Significantly decreased,Operative blood loss (median 1400?mL (range 100 to 9000) versus 150?mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA., Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,326,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Baseline-adjusted average 12-hour FEV1 at end of treatment , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,443,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66),", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,341,3580134,Significantly increased,"Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ? 0.018) [figure 5b].,Both dosages of budesonide/formoterol resulted in a 350 mL (?25%) improvement from baseline to the average over the randomized treatment period in 1-hour post-dose IC, and formoterol resulted in a 210 mL (17%) improvement in 1-hour post-dose IC. Fig. 5", 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,403,2690844,Cannot tell based on the abstract,, Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,403,2690844,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).Table 4", Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,347,3580134,Significantly decreased,"In addition, significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ? 0.004) [see figure S2 in the supplementary material].", Amount of exacerbations per patient-treatment year , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,231,3090298,Cannot tell based on the abstract,, Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,231,3090298,Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA.", Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,389,2690844,Cannot tell based on the abstract,, Smaller incision  , Midline incision , Transverse incision ,0,
edin,389,2690844,Significantly increased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).", Smaller incision  , Midline incision , Transverse incision ,0,
edin,482,2899760,No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused., clinical outcomes , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,367,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Overall use of daily rescue medication improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,402,2690844,Cannot tell based on the abstract,, Urinary retention , Midline incision , Transverse incision ,0,
edin,402,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Urinary retention , Midline incision , Transverse incision ,0,
edin,283,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Overall survival , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,397,2690844,Cannot tell based on the abstract,, Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,397,2690844,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65)., Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,233,3090298,Cannot tell based on the abstract,, Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,233,3090298,No significant difference,Visual acuities were not statistically different between the groups at 3 or 6 months., Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,254,1831737,Cannot tell based on the abstract,, Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,254,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,282,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Time to treatment failure , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,447,2607225,Cannot tell based on the abstract,, cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,447,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months.", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,385,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Bladder training plus tolterodine (Co) ,0,
edin,467,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,305,2817867,Cannot tell based on the abstract,, Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,305,2817867,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.", Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,273,2691927,Cannot tell based on the abstract,, Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,273,2691927,No significant difference,"Nasogastric decompression could be stopped after 2?3 days in both groups (Table 4).Table 4,<td align=""left"">Median duration of nasogastric decompression (days) + IQR</td><td align=""char"" char=""("">2.0 (3.0)</td><td align=""char"" char=""("">3.0 (1.3)</td><td align=""char"" char=""."">0.334</td>", Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,456,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,456,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,269,2691927,Cannot tell based on the abstract,, Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,269,2691927,No significant difference,"Time to discharge was similar for the two groups, with a median difference of 1.5 days (Table 4),<td align=""left"">Median hospital stay (days) + IQR</td><td align=""char"" char=""("">6.5 (9.3)</td><td align=""char"" char=""("">8.0 (7.3)</td><td align=""char"" char=""."">0.235</td>", Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,463,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,238,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,238,3090298,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).", Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,265,2691927,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 3 , Conventional open approach , Laparoscopic surgery ,0,
edin,395,2690844,Cannot tell based on the abstract,, Average patient's weight , Midline incision , Transverse incision ,0,
edin,395,2690844,No significant difference,"Furthermore, no differences were found in the body mass and average length between the two groups (Table 1).", Average patient's weight , Midline incision , Transverse incision ,0,
edin,264,2691927,Significantly decreased,"he VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 1 , Conventional open approach , Laparoscopic surgery ,0,
edin,278,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Anxiety , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,370,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Cough score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,479,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,261,1831737,Cannot tell based on the abstract,, Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,261,1831737,Significantly increased,"In the general population sample interviewed in the follow-up survey, 1,779 (35%) and 647 (13%) of 5,098 respondents reported attending an HIV/AIDS meeting and a programme meeting, respectively (Table 5). More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33?1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52?5.17], p < 0.001),", Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,387,2721929,Cannot tell based on the abstract,, Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,387,2721929,No significant difference,"No difference was observed between the To and Co groups.,When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively).", Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,276,2375236,Cannot tell based on the abstract,, Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,276,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,237,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,237,3090298,Significantly decreased,"The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131), while patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively", Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,298,1871574,Cannot tell based on the abstract,, Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,298,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,428,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,428,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,292,1871574,Cannot tell based on the abstract,, Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,292,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>,<td></td><td colspan=""5""><hr></td>", Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,423,1187893,Significantly increased,"<td colspan=""7""><hr></td>", Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months , No exercise , Exercise ,0,
edin,323,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours on the day of randomization , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,295,1871574,Cannot tell based on the abstract,, Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,295,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,316,3580134,Significantly increased,"lthough improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,217,1475568,Cannot tell based on the abstract,, Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,217,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men.,Regardless of these differences, none were statistically significant.", Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,258,1831737,Cannot tell based on the abstract,, Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,258,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,448,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,448,2607225,Significantly decreased,"Appetite loss decreased from 3 to 6 months (mean=5.1?3.7, s.d.=14.2?11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,441,2600646,Cannot tell based on the abstract,, Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,441,2600646,No significant difference,"<td colspan=""8""><hr></td>", Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,377,3580134,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 ?g and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 ?g and formoterol groups (p = 0.044) at end of treatment., 24-hour urinary cortisol at 6 months , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,218,1475568,Cannot tell based on the abstract,, Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,218,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking ?-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.", Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,255,1831737,Cannot tell based on the abstract,, Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,255,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,393,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day three after surgery , Midline incision , Transverse incision ,0,
edin,289,1871574,Cannot tell based on the abstract,, Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,289,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,473,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008)., First hemodialysis success , Placebo , Clopidogrel ,0,
edin,228,1475568,Cannot tell based on the abstract,, Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,228,1475568,No significant difference,"Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81).", Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,275,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis enquiry , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,401,2690844,Cannot tell based on the abstract,, Cardiac complications , Midline incision , Transverse incision ,0,
edin,401,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Cardiac complications , Midline incision , Transverse incision ,0,
edin,310,3580134,Significantly increased,Time to discontinuation was significantly (p ? 0.004) prolonged in both budesonide/formoterol groups versus placebo., Time to discontinuation , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,355,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Breathlessness Cough and Sputum Scale improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,287,1871574,Cannot tell based on the abstract,, Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,287,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,427,1187893,Cannot tell based on the abstract,, Functional performance improvement , No exercise , Exercise ,0,
edin,427,1187893,No significant difference,"<td colspan=""7""><hr></td>", Functional performance improvement , No exercise , Exercise ,0,
edin,290,1871574,Cannot tell based on the abstract,, Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,290,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,391,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day one after surgery , Midline incision , Transverse incision ,0,
edin,384,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Tolterodine only (To) ,0,
edin,259,1831737,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities., Self-reported STI symptoms , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,407,2690844,Cannot tell based on the abstract,, Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,407,2690844,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance., Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,226,1475568,Cannot tell based on the abstract,, Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,226,1475568,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).", Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,368,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Dyspnoea score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,611,5577662,Cannot tell based on the abstract,, percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,611,5577662,Significantly decreased,"<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,571,5602855,No significant difference,The EQ-5D-3L summary index is shown in Fig.Â 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (pÂ =Â 0.26) or inadequate (pÂ =Â 0.71) motivation/capability during the three years of follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,578,4577567,Significantly decreased,"Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.,In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).", internal work , free stride frequency , stride frequency manipulation ,0,
edin,495,2253708,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th>", 7-day point prevalence abstinence , Practitioner-delivered brief advice , Tailored letters ,0,
edin,619,4139977,No significant difference,Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910)., Improvement in bowel habit ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,608,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>,<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,595,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ??time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85),", Full return to normal work/employment , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,593,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Wearing clothes that show the legs , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,551,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,617,5062234,Significantly decreased,"The visual analog scale scores at rest and on coughing were significantly higher in the local infiltration group in the immediate postoperative period (P = 0.034 and P = 0.007, respectively).", The visual analog scale scores at rest and on coughing , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,544,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,544,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, I was not able to find any connection in text between health care workers with IgG against Severe acute respiratory syndrome and the risk of SARS infection. 
edin,556,4785315,Significantly decreased,"The prespecified comparison for women with two or more social risk factors showed a statistically significant reduction in mean EPDS (MD â??0.79 (95% CI â??1.56 to â??0.02) p=0.05), although no significant differences were seen in the mean EPDS (mean difference (MD) â??0.59 (95% CI â??1.24 to 0.06)) for all the women recruited.", Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS) , standard maternity care ," additional lay support (in this instance Pregnancy Outreach Workers, POWs) ",0,
edin,519,1261533,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023).", Decrease in haematocrit level at day 7 , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,620,4139977,No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372), Table 2.", quality-of-life  ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,583,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â?? 2 ).", Bending the legs without discomfort , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,599,4819709,Significantly decreased,"Return to â??walking short distances without discomfortâ??, â??walking long distancesâ??, â??looking after childrenâ?? and â??full return to normal work/employmentâ?? took longer for the EVLA group than the UGFS group."," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasoundâ??guided foam sclerotherapy , Endovenous laser ablation ,0,
edin,582,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,582,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, Required info can't be found in abstract and there are no other sections for this article. 
edin,560,2888205,Significantly decreased,"<th></th><th colspan=""6""><hr></th>", pain , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,485,2806484,No significant difference,"184 (24%) patients having home and 145 (27%) facility care either had virological failure, were lost to follow-up, or withdrew from the trial (adjusted rate ratio [RR] 0Â·88, 95% CI 0Â·70â??1Â·10).", Virological failure , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,500,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in consistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,561,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", six-minute walk test , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,534,3198285,Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean Â± SEM 47 Â± 1 vs. 53 Â± 1; P < 0.001)., lowâ??glycemic index , high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,502,2956883,No significant difference,No deaths or serious adverse events were regarded as related to study gels., Adverse events , Placebo gel , PRO2000 gels ,0,
edin,589,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Having a bath or shower , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,601,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , glucose 5% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,510,1964758,Significantly increased,"<td colspan=""4""><hr></td>", 8-year survivorship in patients with osteoarthritis , BioModularÂ® shoulder prosthesis , Initial Nottingham TSR design prosthesis ,0,
edin,615,5062234,No significant difference,The 24 h morphine requirement (mean Â± standard deviation) was 34.57 Â± 14.64 mg in TAP group and 32.76 Â± 14.34 mg in local infiltration group (P = 0.688)., The 24 h morphine requirement , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,602,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,512,2829413,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 Â± 11.38 vs. - 30.07 Â± 10.46%, p < 0.001), LDL-C (48.04 Â± 14.45 vs. 39.52 Â± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 Â± 13.15 vs. - 35.52 Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Â± 18.85 vs. - 32.57 Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Levels of LDL cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
edin,610,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>", global assessment of improvement ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,572,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,522,1261533,Significantly increased,"Of 452 patients, 119 (26.3%) had P. vivax parasitaemia detected during follow up. There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).", P. vivax parasitaemia diagnosed during follow up , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,531,2364680,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4)., wound problem , opening subcutaneous tissues with scalpel , opening subcutaneous tissues with electrocautery ,0,
edin,491,2363351,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).", Overall survival at 3 years , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Î³  ",0,
edin,536,3198285,No significant difference,"Table 4
Pregnancy outcomes by diet group,<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,501,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in inconsistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,498,2364533,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).", Preterm delivery , Placebo , Erythromycin ,0,
edin,487,2806484,Significantly decreased,"Table 6 shows mean yearly health services cost per patient calculated during 4 years, (including capital and recurrent expenses, and those of the starting phase and subsequent years). A large proportion of the costs were for drugs and staff salaries. The main cause of excess expenditure for the facility-based group was the increased number of contacts with health staffâ??especially with nurses and medical officers. These costs outweighed those of transport for field officers in the home-based group. Patient costs (transport of patient and companion, lunches, child care, and time lost from work) were much higher for the facility-based than for the home-based group (table 6).", Costs for the health service , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,609,5577662,Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (PÂ â?¤Â 0.0139 for all)., Mean change in nodular consistency and hardness ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,591,4819709,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Doing housework</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">2Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">2Â·10 (1Â·72, 2Â·56)</td>,Table 2
Behavioural recovery: ultrasoundâ??guided foam sclerotherapy versus surgery", Doing housework , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,539,2722000,Significantly decreased,"The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).", rebleeding , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,543,2650992,No significant difference,"Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,573,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,573,5602855,No significant difference,"At the four monthsâ?? follow-up, 112 (80.6%) subjects with good motivation/capability and 26 (39.4%) with inadequate motivation/capability continued self-assessment of pulse daily.,Irregular pulse findings were not significantly associated with the composite outcome variable (pÂ =Â 0.06), stroke/TIA (pÂ =Â 0.48), pacemaker implantation (pÂ =Â 0.10) or death (pÂ =Â 1.00).,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up.", Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,533,3221331,Cannot tell based on the abstract,, did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,533,3221331,No significant difference,"In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.", did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,314,3580134,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 Î¼g compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a]., Pre-dose FEV1 improvement , Placebo , Budesonide/formoterol pMDI 320/9 Î¼g ,0,
edin,604,5062194,No significant difference,There were no between-group differences regarding the neonatal outcome., neonatal outcome ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,741,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,741,3446002,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001), Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,922,3015551,No significant difference,"Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).", Outpatient recovery , undergo a tubal resection after bipolar coagulation with Kleppinger forceps , undergo a tubal resection after Pomeroy ligation ,0,
edin,966,5372931,Cannot tell based on the abstract,, 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,966,5372931,Significantly increased,"The linear dose response for each plasma metabolite was assessed and of the 60 identified metabolites, 14 (poly)phenol metabolites displayed a linear dose-response curve (r2 â¥ 0.89) in plasma (Figure 1) with slopes significantly different from zero (p < 0.05): caffeic acid 4-O-Ã-d-glucuronide and quercetin-3-O-Ã-d-glucuronide displayed r2 > 0.98, while ferulic acid 4-O-Ã-d-glucuronide, 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, ferulic acid, caffeic acid 3-O-Ã-d-glucuronide, sinapic acid, ferulic acid 4-O-sulfate, 3-hydroxybenzoic acid and syringic acid exhibited r2 > 0.90.,The time to reach Cmax (Tmax) varied depending on the metabolite and depending on the amount of (poly)phenols in the juice (Supplementary Figure S1). The level of TP in cranberry juice seemed to impact the Tmax of individual metabolites, for example the Tmax for 3-(4-hydroxyphenyl) propionic acid varied between 7.2 h (409 mg TP juice) and 13.8 h (787 mg TP juice).", 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,869,5332972,Significantly increased,"The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", TUG: Timed âUp &amp; Goâ? test; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,881,5539984,Cannot tell based on the abstract,, Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,881,5539984,No significant difference,"Mixed-models for EPAS total score (see Table 3) indicated a significant effect of time (bÂ =Â 0.07, pÂ <Â 0.001), but no significant group by time interaction effect (bÂ =Â 0.02; pÂ =Â 0.258). This means with regard to the parameterisation of the mixed effects model that there was a significant change of overall empowerment in the control group, but NWpG-IC treatment had no additional effect on improvement of overall empowerment during the 18Â month study period.", Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,635,4106715,Cannot tell based on the abstract,, Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,635,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19â52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,829,4819709,Cannot tell based on the abstract,, Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,829,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Walking long distances (&gt;â20 min)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">8Â·0</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·76 (1Â·45, 2Â·14)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ),The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ", Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,676,3387601,Cannot tell based on the abstract,, side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,676,3387601,No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients., side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,699,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,699,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â0.89) (Table 2).", Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,948,4693888,Cannot tell based on the abstract,, CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,948,4693888,No significant difference,"CKMB AUC (878 Â± 549 vs. 778 Â± 439 h*U/l, non-inferiority p < 0.001) and Troponin-T AUC (12990 Â± 8347 vs. 13498 Â± 6513 h*pg/ml, non-inferiority p < 0.001) was similar in both groups.", CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,688,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,919,3616124,Cannot tell based on the abstract,, preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,919,3616124,No significant difference,"Hp phenotype was not significantly associated with the risk of the primary outcome, preeclampsia, severe preeclampsia, or early onset preeclampsia in white/other, Hispanic or black women (Table 2).", preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,778,2722000,Cannot tell based on the abstract,, The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,778,2722000,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).", The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,833,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ?time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85), looking after children (1Â·45, 1Â·04 to 2Â·02) and walks of short (1Â·48, 1Â·19 to 1Â·84) and longer (1Â·32, 1Â·05 to 1Â·66) duration.", Looking after children , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,943,5551012,Significantly decreased,"However, antibiotic use less than 24Â h to delivery was associated with a decrease in mean APGAR score.", mean Apgar , no antibiotics , antibiotics in less than 24 h to parturition ,0,
edin,812,5602855,No significant difference,Quality of life and number of outpatient clinic visits remained unchanged during follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,897,1198254,Significantly increased,ME-3 was well tolerated and a significant increase in total faecal lactobacilli yet no predominance of ME-3 was detected in all study groups., total fecal counts of lactobacilli , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,871,5209819,Cannot tell based on the abstract,, Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,871,5209819,No significant difference,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8â69.6%) with no difference between intervention districts., Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,825,4819709,Cannot tell based on the abstract,, Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,825,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Lifting heavy objects without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">9Â·8</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·97 (1Â·59, 2Â·44)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,647,1201146,Cannot tell based on the abstract,, Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,647,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,814,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,814,5602855,Invalid Prompt,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,1," There is Self-detected pulse irregularity and outcome events section of the article. However, motivation/capability is not mentioned in it or I was not able to find it. "
edin,941,3039191,Cannot tell based on the abstract,, the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,941,3039191,No significant difference,"The results of FDT perimetry testing are shown in Figs. 1, 2, and 3. There were no statistically significant differences for MD and PSD between the clear IOL and Hoya YA60BBR IOL groups (MD: clear IOL, -5.09 Â± 4.72 Db; Hoya YA60BBR IOL, -3.68 Â± 3.83 dB; p = 0.21 / PSD: clear IOL, 4.26 Â± 2.45 dB; Hoya YA60BBR IOL, 3.81 Â± 1.99; p = 0.27, Mann-Whitney U-test).", the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,937,4918678,Significantly increased,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Reading , nothing , soundfield amplification devices in the classroom ,0,
edin,793,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", pain during movement , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,880,4088715,Cannot tell based on the abstract,," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,880,4088715,Significantly increased,"Subjects in the nCPAP group had a greater improvement for various parameters compared with the standard group including TV (0.8 l, 0.3 l), EtCO2 (30 mmHg, 38 mmHg) and RSBI (39, 150), respectively."," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,846,5062194,Significantly increased,"Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,Preeclamptic parturients premedicated with midazolam (0.035 mg/kg) before spinal anesthesia have lower anxiety and higher postoperative satisfaction levels, with no adverse effects on the newborns.", postoperative satisfaction ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,907,5816054,Cannot tell based on the abstract,, The duration of nebulization , 0.9% saline , furosemide ,0,
edin,907,5816054,No significant difference,"The duration of nebulization was not significantly different across treatments: 0.9% saline, 35.7 Â± 1.0 min; 40 mg furosemide, 36.4 Â± 1.2 min; and 120 mg furosemide, 39.2 Â± 1.1 min (p = 0.075).", The duration of nebulization , 0.9% saline , furosemide ,0,
edin,956,3330821,Cannot tell based on the abstract,, The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,956,3330821,Significantly increased,The overall satisfaction score for the services was 3.57 (3.31 to 3.81) for the EAP alone group and 4.42 (4.17 to 4.67) for the tCBT +EAP group (p<0.001)., The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,884,5514258,Significantly increased,"Patients in the high-risk group had greater survival (hazard ratio [HR], 0.76; P = .002; 95% confidence interval [CI], 0.64-0.91) if they received adjuvant radiation therapy.", survival , major salivary gland cancer in high risk group without adjuvant radiation therapy , major salivary gland cancer in high risk group plus adjuvant radiation therapy ,0,
edin,677,2430614,Significantly decreased,"In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, pâ=â0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, pâ=â0.005).", the parasitological and clinical failure rate at day 28 post treatment , artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,673,3387601,No significant difference,"hose in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,In children with GBS requiring MV, PE is superior to IVIG regarding the duration of MV but not PICU stay or the short term neurological outcome.", Pediatric Intensive Care Unit (PICU) stay , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,942,5551012,No significant difference,"Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores."," birthweight, incidence of congenital birth defect and mean Apgar scores ", no antibiotics , antibiotics ,0,
edin,638,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,638,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,868,5332972,Cannot tell based on the abstract,, FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,868,5332972,Significantly increased,"**Significant difference p<0.01. SD: standard deviation; FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; TUG: Timed âUp & Goâ? test; 10MWT: 10-m walk test; CGS: comfortable gait speed; FGS: fast gait speed,The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,650,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,650,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,824,4819709,Cannot tell based on the abstract,, Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,824,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,859,4139977,No significant difference,"After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).", decrease in abdominal pain and distension severity ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,683,2447617,Significantly increased,The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01)., The modified Functional Independence Measure scores , placebo , progesterone ,0,
edin,770,2361948,Cannot tell based on the abstract,, 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,770,2361948,Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42â72%) and 27% (95% CI: 14â40%) for patients receiving 16âGy/2 fr, and 30% (95% CI: 18â42%) and 11% (95% CI: 3â20%) for patients receiving 20âGy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).", 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,959,2656477,Significantly increased,<td></td><td></td><td></td><td></td><td></td><td></td>, self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors. , usual care , lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification ,0,
edin,717,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,811,5256321,Cannot tell based on the abstract,," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,811,5256321,Significantly increased,"Table 3 shows that the experimental group showed significant improvements in all testsâBBS (p=0.001), TUG (p=0.001), forward FRT (p=0.001), affected lateral FRT (p=0.001), and unaffected lateral FRT (p=0.002)âwhen the values before and after training were compared in each group"," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,935,4264479,No significant difference,All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR)., blood-stage infection , minimally exposed volunteers for both antigens , definitely exposed volunteers for both antigens  ,0,
edin,730,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question formed and no provided answers. 
edin,885,5514258,No significant difference,"In contrast, patients in the intermediate- (HR, 1.01; P = .904; 95% CI, 0.85-1.20) and low-risk groups (HR, 0.85; PÂ =Â .427; 95% CI, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.", survival , major salivary gland cancer in low/intermediate risk group without adjuvant radiation therapy , major salivary gland cancer in low/intermediate risk group plus adjuvant radiation therapy ,0,
edin,939,4918678,Cannot tell based on the abstract,, Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,939,4918678,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">âEG</td><td align=""center"" colspan=""1"" rowspan=""1"">131.8</td><td align=""center"" colspan=""1"" rowspan=""1"">59.9</td><td align=""center"" colspan=""1"" rowspan=""1"">112.9</td><td align=""center"" colspan=""1"" rowspan=""1"">52.8</td><td align=""center"" colspan=""1"" rowspan=""1"">1.31 (9)</td><td align=""center"" colspan=""1"" rowspan=""1"">.221</td>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,658,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,658,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,938,4918678,Cannot tell based on the abstract,, Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,938,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,680,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,680,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,809,5256321,Cannot tell based on the abstract,, The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,809,5256321,Significantly increased,"The 10mWT improved significantly (p=0.001) in the experimental group (using the Spine Balance 3D system) but not in the control group, and core muscle strength, which we checked using Spine Balance 3D system evaluation program, improved more in the experimental group as well.", The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,783,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", overall drain output , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,675,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,712,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,622,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,622,3187863,No significant difference,here was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,911,2774638,Cannot tell based on the abstract,, obtained calcium from dairy  , black women , white women ,0,
edin,911,2774638,Significantly increased,"White women obtained more calcium (630 [423] mg) from dairy than did black women (424 [373] mg, P < .004).", obtained calcium from dairy  , black women , white women ,0,
edin,777,3198285,Cannot tell based on the abstract,," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,777,3198285,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,691,2899760,Cannot tell based on the abstract,, Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,691,2899760,Significantly increased,"he fusion rate shown by the radiological analysis is presented in TableÂ 4. All patients in group III (clearly non-fused) showed at least 4Â° of mobility (the limit for the group set by the classification was 3.0Â°). There was no statistically significant difference in the fusion rate between smokers (92%) and non-smokers (74%) (PÂ =Â 0.2). Smokers operated on with TM showed an 87% fusion rate. Kappa analysis showed 0.63 and 0.66 for the intra-observer correlation, and 0.58 for inter-observer correlation.TableÂ 4,Radiological fusion

Fusion group	TM	SR
No.	Percentage	No.	Percentage
I (clearly fused)	18	46	35	89
IIA (probably fused)	9	23	1	3
IIB (probably non-fused)	5	13	0	0
III (clearly non-fused)	7	18	3	8
Fusion rate (IÂ +Â IIA)		69		92,his study of uninstrumented single-level ACDF showed a lower fusion rate with Trabecular Metal than with the SmithâRobinson technique with autograft after single-level anterior cervical fusion without plating.", Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,909,2774638,Significantly increased,"The CFFFQ estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).", Estimation of total daily calcium intake , 24-hour recall , calcium-focused food frequency questionnaire (CFFFQ) ,0,
edin,887,5801479,Significantly decreased,"Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1Î² (P = 0.02), tumor necrosis factor alpha (TNF-Î±) (P = 0.02) and interferon gamma (IFN-Î³) (P = 0.03) in PBMCs of diabetic HD patients."," gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?)  ", placebo (n = 30) every 2 weeks for 12 weeks ," vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks ",0,
edin,781,2722000,Cannot tell based on the abstract,, Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,781,2722000,No significant difference,Total mortality and 30-day mortality were not different between the two groups (Table 7)., Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,672,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", Period of mechanical ventilation  , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,703,3187863,No significant difference,"here were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,719,1201146,Significantly increased,"<td colspan=""3""><hr></td>"," Pain, physical function, PGA, stiffness  ", vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,841,4819709,Cannot tell based on the abstract,," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,841,4819709,Significantly increased,"Participants randomized to EVLA recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 3). Return to âhaving a bath or showerâ was quicker after surgery than after EVLA. There was no difference in time to return to the participation behaviour of âwearing clothes that show the legsâ.,<td align=""left"" colspan=""1"" id=""bjs10081-ent-0450"" rowspan=""1"" valign=""top"">Participation items</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0451"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0452"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0453"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0454"" rowspan=""1"" valign=""top""></td>"," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,726,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,726,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,784,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,877,2974815,No significant difference,There was no difference in the percentage of patients with controlled blood pressure in the âphone callsâ? group and âno phone callsâ? group or in the âtraditionalâ? and âcurrentâ? groups., The percentage of patients with controlled blood pressure (&lt;140/90 mmHg) , âno phone callsâ? group , phone callsâ? group ,0,
edin,646,1201146,Cannot tell based on the abstract,, good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,646,1201146,Significantly increased,"<td colspan=""3""><hr></td>", good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,740,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,740,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,727,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,906,4320624,Cannot tell based on the abstract,," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,906,4320624,Significantly increased,"Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â24 was significantly higher for all doses of abediterol versus placebo (pâ<â0.0001 for all, TableÂ 2), with dose-related effects observed."," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,918,3616124,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Hispanic</td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>", preeclampsia risk  in Hispanic Hp 2-2 women. , placebo from 9-16 weeks gestation until delivery. , daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery. ,0,
edin,864,4078386,No significant difference,"We didnât find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05).", mean of HCV-RNA numbers 6 months after treatment  , placebo , 20 mg atorvastatin nightly for 3 months ,0,
edin,720,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,720,1201146,Significantly decreased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,823,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,823,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, There is no question in this prompt. It contains only a statement 
edin,696,2858204,Cannot tell based on the abstract,," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,696,2858204,Significantly increased,"In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009) (Fig. 2)."," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,632,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,632,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53â12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,873,5729252,Cannot tell based on the abstract,, hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,873,5729252,Significantly increased,"At the time of survival time analysis, hospital-free survival was 358.87âÂ±â68.65Â days (meanâÂ±âSE) (median, 331Â days) in the untreated group, which was significantly different from that in the drug-treated group (603.44âÂ±â50.074Â days) as assessed by proportional hazard analysis (hazard ratio of the drug-treated group to the untreated group, 0.19, Pâ=â0.017; log-rank test, Pâ=â0.019; and Wilcoxon test, Pâ=â0.014).", hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,928,4192987,Cannot tell based on the abstract,, Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,928,4192987,No significant difference,The difference in median was not statistically significant for serum 17-hydroxyprogesterone and testosterone levels [Tables 2 and 3]., Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,639,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,639,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,645,1201146,Cannot tell based on the abstract,, 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,645,1201146,Significantly increased,"<td colspan=""3""><hr></td>", 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,747,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,890,5519461,No significant difference,"The eradication rates of the EAC and RAC regimens were 79.8% (95% confidential interval: 71.7-89.0%) and 74.7% (66.0-83.4%), respectively, in a per protocol (PP) analysis (p=0.488). The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286).", H. pylori eradication ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,736,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,736,2720945,Significantly increased,"<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>,As primary outcome measure the sum of exacerbations for frequency, duration and severity at all 6 following visits as composite endpoint (equally weighted) were calculated according to the Wei-Lachin Test procedure for multiple criteria and showed a statistically significant difference for the primary outcome measure between both treatment groups (p = 0.0120) Table 3."," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,865,5680306,Significantly increased,Serum 25(OH)D concentrations increased with vitamin D supplementation compared to placebo (pâ<â0.001)., Serum 25(OH)D concentrations ," the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks "," vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily ",0,
edin,732,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,732,2607225,Significantly decreased,"Global quality of life, emotional functioning, cognitive functioning, pain, insomnia, appetite loss, anxiety, depression, intrusion and avoidance improved from baseline to 3 months. Financial difficulties worsened from baseline to 3 months. Global quality of life, physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea/vomiting, appetite loss, diarrhoea, financial difficulties, and depression improved from 3 to 24 months.,Appetite loss decreased from 3 to 6 months (mean=5.1â3.7, s.d.=14.2â11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,967,5372931,Cannot tell based on the abstract,," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,967,5372931,Significantly increased,"Linear regression analysis was performed between the TP level in the intervention and the AUC of each class of compounds. The AUC for flavonols produced the highest r2 (0.97, p < 0.001), followed by the valerolactones (r2 = 0.89, p < 0.005), benzoic acids (r2 = 0.85, p < 0.01), cinnamic acids (r2 = 0.72, p < 0.05), phenylacetic acids (r2 = 0.71, p < 0.05), benzaldehydes (r2 = 0.65, p < 0.05); hippuric acids, pyrogallols, and catechols did not show a linear dose response."," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,792,125315,Cannot tell based on the abstract,, The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,792,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>,<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,934,4264479,Cannot tell based on the abstract,, blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,934,4264479,No significant difference,"ll volunteers were diagnosed with malaria [see Table S5 for criteria for treatment and Table S6 for time to diagnosis (TTD) and parasitemia at diagnosis] with the exception of one volunteer in Group 2 (Volunteer 110), who was asymptomatic and blood film negative at all time-points, despite blood-stage infection confirmed by qPCR", blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,961,2656477,Cannot tell based on the abstract,, depression , no weight lost , lost weight ,0,
edin,961,2656477,No significant difference,"<td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td>", depression , no weight lost , lost weight ,0,
edin,660,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,660,2720945,Significantly decreased,"Table 3
Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*,<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>"," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,891,5519461,No significant difference,The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286)., Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype. ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).,<td align=""left"">âMortality at 60 days</td><td align=""center"">15 (55.6)</td><td align=""center"">14 (46.7)</td><td align=""center"">0.599</td>,Table 2
Clinical outcomes according to treatment group", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,679,2430614,Cannot tell based on the abstract,, parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,679,2430614,No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups (Table 6)., parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,883,5539984,Cannot tell based on the abstract,, reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,883,5539984,No significant difference,"However, as indicated by the non-significant group by time interaction, there was no difference between groups regarding the reduction of total needs (bÂ =Â 0.09; pÂ =Â 0.217) or the increase of met needs (bÂ =Â 0.01; pÂ =Â 0.621).", reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,Cannot tell based on the abstract,, prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,No significant difference,"<td>number of psychiatric inpatient admissions [+ 1]</td><td>1.131</td><td>1.045</td><td>-</td><td>1.225</td>,The results of the mixed effects logistic regression model (not presented) did neither show differences of the prevalence of psychiatric inpatient admission between groups during the six months before baseline assessment (OR 0.99; pÂ =Â 0.985), nor a change over time (OR 0.62; pÂ =Â 0.086) in either groups or a difference between the groups (OR 0.97; pÂ =Â 0.878) during the study period.", prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,900,1198254,Significantly increased,"Faecal recovery of ME-3 was documented by molecular methods only in fermented milk group, however the significant improvement of blood TAA (Total Antioxidative Activity) and TAS (Total Antioxidative Status) indices was seen both in case of fermented goat milk and capsules"", yet glutathione re-ox ratio values decreased only in case of fermented by ME-3 goat milk.", Total Antioxidative Activity , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,923,5295802,Cannot tell based on the abstract,, cytokine levels at baseline , placebo , levocarnitine ,0,
edin,923,5295802,No significant difference,"here was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown).", cytokine levels at baseline , placebo , levocarnitine ,0,
edin,636,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,694,2858204,Significantly increased,"n the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).", complete healing of the index ulcer at 1-year of follow-up , placebo , hyperbaric oxygen therapy ,0,
edin,925,5295802,Cannot tell based on the abstract,," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,925,5295802,No significant difference,"There was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown)."," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,763,2447617,Cannot tell based on the abstract,, The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,763,2447617,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034)., The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,794,2830179,Cannot tell based on the abstract,, Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,794,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>,<td align=""left"">Pain on rest (0-10)</td><td align=""center"">3.0 (2.7)</td><td align=""center"">1.4 (1.8)</td><td align=""center"">1.1 (2.2)</td><td align=""center"">2.0 (2.6)</td><td align=""center"">-1.9 (2.3)</td><td align=""center"">0.6 (1.0)</td><td align=""center"">-2.0 (-3.8 to -0.2)</td>,<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,813,5602855,Cannot tell based on the abstract,, Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,813,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,936,4918678,Cannot tell based on the abstract,, Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,936,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,896,4140547,Cannot tell based on the abstract,, Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,896,4140547,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>,<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>", Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,644,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,644,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,684,2447617,Significantly decreased,The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05)., The mortality rate , placebo , progesterone ,0,
edin,764,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,716,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,742,1913177,Cannot tell based on the abstract,, Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,742,1913177,No significant difference,"Major wound complications were found in 10 of the 19 patients in the CST group: wound infection (n = 3), skin necrosis (n = 2), hematoma (n = 1). Four patients developed seroma; these were not associated with the aforementioned complications.,Major wound complications were found in 13 of the 18 patients in the e-PTFE group: wound infection (n = 2), skin necrosis (n = 3), hematoma (n = 1).", Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,892,5618071,Cannot tell based on the abstract,," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,892,5618071,Significantly decreased,"As a global result (G1 + G2), a significant decrease in the total score was observed in ADI-R, ABC, and ATEC scales one month after the intervention (Wilcoxon matched pair test; ABC, Z = 3.823, p = 0.000131; ADI-R, 3.337, p = 0.000846; ATEC, Z = 3.723, p = 0.000196)."," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,665,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,665,3446002,Significantly decreased,"Clofibrate group (group I) was given a single dose of 50 mg/kg clofibrate before starting phototherapy. I,<td align=""left"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>TSB<xref ref-type=""table-fn"" rid=""TF0002"">*</xref> (mg/dl)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.24 (1.48)</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.42 (1.44)</td>,TSB: total serum bilirubin,<td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>Control (II)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">30</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">12.6 (1.44)</td>", Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,640,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,843,2891743,Significantly increased,"<td colspan=""4""><hr></td>,<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,1180,5002324,Significantly increased,"After training, participants in the balance-based exergaming group showed significant improvements in LOS performance, and in the eyes-closed condition of the OLS test.", the limits of stability (LOS) performance and one-leg stance (OLS) tests , a balance training group for an 8-week balance training period. , a balance-based exergaming group for an 8-week balance training period. ,0,
edin,1115,3423952,Cannot tell based on the abstract,," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1115,3423952,Significantly increased,"Main effects for PGE2 concentrations in synovial fluid were not detected (P > 0.05); however, after adjusting the data by subtracting the PRE value from each POST value, and evaluating changes relative to pre-exercise values, effects of exercise (P = 0.03) and joint (P = 0.04) were detected (Figure 2(b)).,Similar to synovial fluid CS concentrations, there were greater relative increases (P = 0.04) in PGE2 concentrations in hock joints when compared to carpus joints (Figure 2(b))."," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1061,3787573,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Western Ontario and McMaster Universities Osteoarthritis Index for stiffness , Exercise alone , NMES plus exercise ,0,
edin,1004,3442969,Cannot tell based on the abstract,, Disease control rates , CAPOX , FUFOX ,0,
edin,1004,3442969,No significant difference,"Disease control rates (DCR) were 77%, 81% and 88%, respectively, which was not statistically significant (Table3, pâ=â0.29).", Disease control rates , CAPOX , FUFOX ,0,
edin,1168,5354011,Cannot tell based on the abstract,, willingness?to?pay. , before treatment , after treatment  ,0,
edin,1168,5354011,Significantly increased,"The average maximum WTP for treatment for menorrhagia was approximately Â£27 (US$41) per month (see Table 2). The average combined MMAS score for treatment doubled from approximately 43 at preâtreatment to 85 following treatment, generating a statistically significant improvement in health status as measured by this instrument (P = 0.000).", willingness?to?pay. , before treatment , after treatment  ,0,
edin,1080,4565804,Significantly decreased,"Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores.", morphine doses , Placebo , gabapentin (10 mg/kg) ,0,
edin,987,2920262,Cannot tell based on the abstract,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,987,2920262,Significantly increased,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,1130,5225252,Significantly increased,"Gag-specific IFN-Î³ enzyme-linked immunospotâdetermined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for â¥8 months after completion of the prime-boost regimen.", Gag-specific IFN-? enzyme-linked immunospotâdetermined response rates and geometric mean responses , a single dose of Ad35-GRIN or SeV-Gag , groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) ,0,
edin,1015,5101425,No significant difference,No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 Â± 266.2 in group D vs. 406.3 Â± 341.6 in group P (control group); P = 0.208)., Bleeding rate after surgery , Placebo , Desmopressin ,0,
edin,1104,4109867,No significant difference,"Dietary SW supplementation had no effect on saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles."," saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles ", basal diet , 2% seamustard ,0,
edin,1042,5746685,No significant difference,"There were no significant between-group differences in the primary outcome of change in BMI (basic â0.5 (1.9) kg/m2, enhanced â0.5 (1.6) kg/m2, p = 0.93).", Change in body mass index , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1082,5610854,Cannot tell based on the abstract,, intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1082,5610854,Significantly decreased,"7 of the 38 eyes (44.7%, CI: 28.9%â60.5%) in group 1 required a mean of 1.8 IOP-lowering medications while seven of the 111 eyes (6.3%, CI: 1.8%â10.8%) in group 2 required a mean of 1.1 medications (Pearson's chi-square valueâ=â30.940, p < 0.001).", intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1020,3159986,Cannot tell based on the abstract,, Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1020,3159986,No significant difference,"Baseline lung function was normal for all patients with VC being 95.5 Â± 3.7%, FEV1 90.5 Â± 3.6%, PEF 86.9 Â± 4.5%, MVV 93.8 Â± 6.6%, and maximal inspiratory pressure (PImax) 75.1 Â± 5.4% predicted. RMET induced mild but not significant increases in VC (P1: 95.9 Â± 3.5%, P4: 99.2 Â± 4.1%, P = 0.39), FEV1 (P1: 93.1 Â± 2.7%, P4: 96.3 Â± 3.8%, P = 0.28), PEF (P1: 90.0 Â± 4.8%, P4: 95.7 Â± 5.4%, P = 0.07), MVV (P1: 95.6 Â± 6.0%, P4: 101.0 Â± 6.5%, P = 0.24), and PImax (P1: 79.2 Â± 5.4%, P4: 78.0 Â± 6.4%, P = 0.42).", Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1128,5936036,No significant difference,There was no significant difference among the drop-out rates in the three groups., drop-out rates , the SCBT with medication group or regular medication group , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,976,3798949,Cannot tell based on the abstract,, Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,976,3798949,Significantly decreased,"The contribution of extra clinic visits and investigations, in particular CT scans used for response assessment, was significantly higher for commercial compared with non-commercial trials.", Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,1024,4895766,Cannot tell based on the abstract,, Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1024,4895766,Significantly increased,"In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.,The surrounded skin color became normal skin color within 7 days in maximum patients (76%) of Group A, whereas only 32% patients showed normal peri-wound skin color in Group B.", Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1099,4109867,Cannot tell based on the abstract,, IgG concentrations , basal diet , 2% seamustard ,0,
edin,1099,4109867,Significantly increased,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgG concentrations , basal diet , 2% seamustard ,0,
edin,1210,4306068,No significant difference,"The mean timing to analgesic administration for the displayed and non-displayed groups were 81.3âÂ±â41.2 (95% C.I 65.9, 96.7) and 88.7âÂ±â45.4 (95% C.I 69.0, 108.3), respectively (pâ>â0.05).", The mean timing to analgesic administration , not displayed in the control. , pain score display group ,0,
edin,1122,5489138,Cannot tell based on the abstract,"he 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1122,5489138,Significantly increased,"3M CDP = 3-month confirmed disability progression;,The 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1132,5225252,Cannot tell based on the abstract,, The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1132,5225252,Significantly increased,"The GMTs were significantly higher (P < .0001, by the Kruskal-Wallis test) in the ASH group after the SeV boost than in the other groups (53, 53, 245, 50, and 59 in the SLA, SHA, ASH, SHSH, and placebo groups, respectively; Figure 4).", The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1165,4223523,Cannot tell based on the abstract,, awake time , placebo , olanzapine ,0,
edin,1165,4223523,Significantly decreased,"As well as an increase in TST, olanzapine treated participants experienced significantly fewer awakenings (TableÂ  2) and less overall time awake compared to treatment with placebo (2-way repeated measures ANOVA; main effect of treatment, number of awakenings, F[1,23]â=â10.0, pâ=â0.004; awake time, F[1,23]â=â4.8, pâ=â0.037).", awake time , placebo , olanzapine ,0,
edin,1141,3895597,No significant difference,"The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.", The incidence of adverse events , octylonium 20 mg , tiropramide 100 ,0,
edin,1106,5064802,No significant difference,"Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), pÂ =Â 0.13].", Postoperative troponin T , no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1177,3752932,Cannot tell based on the abstract,," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1177,3752932,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th>"," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1074,1562433,Significantly increased,"<td colspan=""4""><hr></td>", vastus medialis obliquus (VMO) EMG activity  , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1107,5064802,No significant difference,"No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-Îµ in the human heart."," activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart ", no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1079,4667210,Significantly increased,"Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in < 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).", disappearance in &amp;lt; 3 h  of the MSG symptom complex , maltodextrin (placebo) , Capsules (300 mg) containing Lactobacillus brevis G101 (1Ã1010 CFU/individual) ,0,
edin,1113,3423952,Significantly increased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide."," erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood ", no exercise , exercise ,0,
edin,1013,5018157,No significant difference,"The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 Â± 0.7 versus 7.2 Â± 1.5) (P = 0.001), but there was no significant difference in the five-minute Apgar scores between the two groups.", Five-minute Apgar score , Low-dose bupivacaine spinal anesthesia in healthy parturients , Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients ,0,
edin,1086,4395717,Significantly decreased,"After the intervention, the error angle was significantly smaller in flexion and right left side-bending, and pain was significantly reduced in the upper thoracic manipulation group.", repositioning error in flexion and right and left side-bending and reduction in pain , cervical stability training (CST) , upper thoracic manipulation (UTM) ,0,
edin,979,5619630,Cannot tell based on the abstract,, Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,979,5619630,No significant difference,there was no significant difference between the groupsâ PSLES scores at any follow-up point., Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,1159,3296686,Cannot tell based on the abstract,, serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1159,3296686,Significantly decreased,Pioglitazone treatment decreased at day-14 serum ALT levels (mean changeâ=â7.5 IU/ml; 95% CI: 2.1 to 12.9; Pâ=â0.012) and to a smaller degree serum AST levels (mean changeâ=â2.6 IU/ml; 95% CI: â0.6 to 5.8; Pâ=â0.096) ( Table 5 )., serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,981,5490116,Cannot tell based on the abstract,, Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,981,5490116,Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P < 0.005) higher in Group B compared to Groups A and C at 24 h as shown in Table 2., Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,1198,3743641,Cannot tell based on the abstract,, sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1198,3743641,Significantly increased,"Additionally, in SMART-3 (subjects with vulvovaginal atrophy), the Menopause-Specific Quality of Life questionnaire results at week 12 showed significant improvements in sexual function and total scores with both BZA/CE doses versus placebo or BZA 20 mg (P < 0.001).", sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1054,2223531,No significant difference,"he median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9).,In conclusion, oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.", Median AUC(inf) , Oral etoposide , Oral etoposide phosphate ,0,
edin,1001,3878029,No significant difference,The intervention had no effect on smoking status (p =â.73) or on the number of cigarettes smoked per day (p =â.56)., Cigarettes smoked per day , Relaxation , Hypnotherapy ,0,
edin,999,3074545,Significantly increased,"<td align=""left"">SF36</td><td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>", Improvements in physical and mental wellbeing , Non-mentored group , Non-professional mentor support ,0,
edin,1158,3296686,Cannot tell based on the abstract,, day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1158,3296686,Significantly decreased,Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean changeâ=â8.2 mg/dL; Pâ=â0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean changeâ=â18.8 mg/dL; Pâ=â0.001) ( Table 4 )., day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1191,3743641,Cannot tell based on the abstract,, mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1191,3743641,Significantly decreased,"At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a decrease (P < 0.001) in the adjusted mean daily number of moderate to severe hot flushes, reaching a 74% and a 80% reduction, respectively, representing a clinically meaningful reduction of approximately 7â8 hot flushes per day, compared with a 51% reduction (representing a reduction of approximately five hot flushes per day) in the placebo group (Figure 1).18", mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1075,1562433,No significant difference,"<td colspan=""4""><hr></td>", vastus lateralis longus (VLL) EMG activity , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1038,4588874,Cannot tell based on the abstract,, Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1038,4588874,No significant difference,There were no serious adverse events reported and no subjects were discontinued due to AEs., Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1126,3611646,Cannot tell based on the abstract,, high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1126,3611646,Significantly increased,"With regard to the biochemical parameters, Group A showed highly significant decrease (P`0.01) in serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels, while high density lipoprotein (HDL) increased highly significantly (P`0.01) and a significant decrease (P`0.05) was found in blood urea (13.80%) as well as serum AChE (3.67%) within normal limits [Table 6].,Group A (Trial Group)
Patients of this group were administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar.", high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1057,3787573,No significant difference,"ollowing the interventions, a statistically significant improvement in both groups was observed in all outcomes assessed. For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Numerical Rating Scale , Exercise alone , NMES plus exercise ,0,
edin,1142,3895597,Cannot tell based on the abstract,, the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1142,3895597,Significantly increased,"Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).", the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1100,4109867,Cannot tell based on the abstract,, IgM concentrations , basal diet , 2% seamustard ,0,
edin,1100,4109867,No significant difference,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgM concentrations , basal diet , 2% seamustard ,0,
edin,1145,5851630,Significantly increased,"However, in the ET+TA treatment, ABP values were greater after exercise, except for Fp1.", absolute beta power (ABP) after exercise , PlaceboâPL , Taurine combined with Ethanol (TA+ET) ,0,
edin,1192,3743641,Cannot tell based on the abstract,, mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1192,3743641,Significantly increased,BZA 20 mg/CE 0.45 or 0.625 mg showed a significantly greater increase from baseline in the mean proportion of superficial cells compared with placebo (P < 0.001)., mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1208,4526336,Significantly increased,"Compared to those with normal cognitive function, MCI participants generated a greater proportion of words out of the total number of words during the timed conversation sessions (p=0.01).", proportion of words out of the total number of words , healthy , mild cognitive impairment (MCI) ,0,
edin,1174,4821313,Significantly increased,There was a significant increase in serum creatinine and a decrease in eGFR 48 hr post-intervention in group 1 (short regimen) with no statically difference regarding those parameters group 2 (long regimen)., serum creatinine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1084,5610854,Cannot tell based on the abstract,, The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1084,5610854,No significant difference,The absolute risk for â¥2 lost lines of vision in the trabeculectomy group was 18% (20 of 111) compared to 16% (6 of 38) in the LPI group., The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1156,3296686,Significantly increased,"Although Prednisone did increase serum HCV RNA at day-4 (nâ=â10; change from baselineâ=ââ42,786 IU/ml; 95% CI â85,500 to â15,700; Pâ=â0.049), the log10 HCV RNA titers were statistically not different from baseline day-0.", HCV RNA at day-14 , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1062,5100099,No significant difference,"There were no statistically significant differences on blood pH levels between the two modes of ventilation (7.32âÂ±â0.02 vs. 7.32âÂ±â0.04, Pâ=â0.34).", Blood pH levels , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1028,4486943,Cannot tell based on the abstract,, Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1028,4486943,No significant difference,"TableÂ 3
Estimates of abstinence at 6 and 12âmonths, N=1785,<td colspan=""1"" rowspan=""1"">âStandard</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">66.0 (61.2 to 70.9)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">60.6 (55.6 to 65.6)</td><td colspan=""1"" rowspan=""1"">363</td><td colspan=""1"" rowspan=""1"">65.3 (60.4 to 70.2)</td><td colspan=""1"" rowspan=""1"">362</td><td colspan=""1"" rowspan=""1"">61.6 (56.6 to 66.6)</td>,<td colspan=""1"" rowspan=""1"">âStandard plus TEQ-10</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">69.6 (64.9 to 74.3)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">65.2 (60.4 to 70.1)</td><td colspan=""1"" rowspan=""1"">370</td><td colspan=""1"" rowspan=""1"">67.0 (62.2 to 71.8)</td><td colspan=""1"" rowspan=""1"">371</td><td colspan=""1"" rowspan=""1"">63.1 (58.2 to 68.0)</td>,<td colspan=""1"" rowspan=""1"">âDifference compared to standard</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">1.3 (â5.6 to 8.2)<break>p=0.7121</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">0.5 (â6.6 to 7.6)<break>p=0.8947</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â2.7 (â10.0 to 4.6)<break>p=0.4655</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â5.0 (â12.5 to 2.4)<break>p=0.1871</break></td>", Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1111,4940009,No significant difference,"Overall, the incidence of POM in Group K was significantly less, when compared with Group N (P<0.05), but both groups were comparable based on the grade 2 of POM.", grade 2 of POM ," Group N, the same volume (5 mL) of normal saline was injected "," Group K, 0.5 mg/kg of ketamine was injected intravenously, ",0,
edin,1199,3743641,Cannot tell based on the abstract,, lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1199,3743641,Significantly increased,"In addition, in SMART-1, a statistically significant increase in lumbar spine BMD from baseline to month 24 was observed for both the BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg treatment groups compared with a decrease in lumbar spine BMD in the placebo group (P < 0.001).", lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1203,4280954,Cannot tell based on the abstract,, serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1203,4280954,Significantly decreased,The addition of flaxseed or/and vitamin E to the high-fat diet led to significant reductions of serum glucose levels compared with those in the DM group (Table II)., serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1193,3743641,Cannot tell based on the abstract,, reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1193,3743641,Significantly decreased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P < 0.001) and a significantly greater increase from baseline in the mean proportion of intermediate cells (P < 0.05) compared with placebo at weeks 4 and 12., reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1129,5936036,Cannot tell based on the abstract,," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1129,5936036,No significant difference,"As stated in Table 1, participants in the SCBT group and SCBT with medication group were not significantly different in satisfaction factors, such as the quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met."," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1025,4486943,Cannot tell based on the abstract,, Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1025,4486943,Significantly increased,"Programme engagement was measured as the number of counselling calls completed by participants:1 planned programme counselling calls,2 participant-initiated inbound calls, or3 IVR-transferred counselling calls (table 2). Overall, the average number of total calls completed was 3.9 (SD=1.7; range 2â19). There was a statistical difference between groups; the TEQ-10 and TEQ-20 groups completed slightly more calls than the standard study group due to the additional IVR-transferred counselling calls they received after a positive screen (p<0.001).", Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1017,5101425,Cannot tell based on the abstract,, Hb levels , Placebo , Desmopressin ,0,
edin,1017,5101425,No significant difference,"A paired T-test revealed that the Hb levels decreased significantly in each group after surgery (P = 0.0001), but the difference was not statistically significant between the groups (0.134).", Hb levels , Placebo , Desmopressin ,0,
edin,1144,4893237,Cannot tell based on the abstract,, mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1144,4893237,Significantly increased,"In this study 13 participants died within 30Â days of sustaining the index hip fracture. T,The participants who died during hospitalization due to a cardiovascular event all had a history of cardiovascular disease. The three participants who died after discharge but within 30Â days of the index hip fracture did so due to a cerebrovascular event, a myocardial infarction and a pulmonary emboli, respectively.", mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1201,3743641,Cannot tell based on the abstract,," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1201,3743641,No significant difference,"No apparent increased risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, was observed with either dose strength of BZA/CE."," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1114,3423952,Significantly decreased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide.", plasma nitric oxide , no exercise , exercise ,0,
edin,1022,4895766,Cannot tell based on the abstract,, Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1022,4895766,Significantly increased,The strength and positive finding of this study is Katupila Kalka had the potential to cure the diabetic wounds early than Betadine ointment., Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1136,4627811,Cannot tell based on the abstract,, Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1136,4627811,No significant difference,There was no significant change in the SF-36 total score (Table 5)., Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1189,5122238,Cannot tell based on the abstract,," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1189,5122238,No significant difference,Mean central temperature from 0 to 60 min recovery in the three groups (P = 0.64)," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1064,5100099,Significantly increased,"With regard to hemodynamics, systolic arterial pressures were higher using NAVA: +8.4Â % (95Â % CI: +3.3 to +13.6Â %, Pâ=â0.03).", Systolic arterial pressure , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1041,5746685,No significant difference,"There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%) and limited change in secondary outcomes for either program.", Weight rebound after 12 months , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1173,4821313,Cannot tell based on the abstract,, the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1173,4821313,No significant difference,"Regarding the pH of urine, we found that it was (5.95 Â± 0.26) in group 1 and (5.97 Â± 0.24) in group 2, showing no statistical difference and highlighting the fact that both regimen had almost the same alkalinizing efficacy with no proven extra benefit for patients with pH values greater than 6.", the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,971,3491047,No significant difference,"No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.", Total adherence to the program , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,968,5372931,Cannot tell based on the abstract,, 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,968,5372931,Significantly increased,"A positive, linear dose response for total excretion over 24 h of each urinary metabolite was assessed and of the 60 identified metabolites, 12 (poly)phenol metabolites displayed a positive linear dose-response curve (r2 â¥ 0.66) in urine with slopes significantly different from zero (p < 0.05); they were: 2,3-dihydrobenzoic acid (r2 = 0.79), 2,4-dihydrobenzoic acid (r2 = 0.77), dihydrocaffeic-3-O-sulfate (r2 = 0.66), ferulic-O-4-sulfate (r2 = 0.89), o-courmaric acid (r2 = 0.72), quercetin-3-O-Ã-d-glucuronide (r2 = 0.89), 2,5-dihydroxybenzoic acid (r2 = 0.80), chlorogenic acid (r2 = 0.72), p-coumaric acid (r2 = 0.90), sinapic acid (r2 = 0.85), benzoic acid (r2 = 0.99), isoferulic acid (r2 = 0.74).", 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,1157,3296686,Significantly decreased,"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (nâ=â10; difference of meansâ=â205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001).", HCV RNA at day-14 , baseline , Prednisone (40 mg/day for 4 days) ,0,
edin,1101,4109867,Significantly decreased,Dietary SW significantly reduced meat cholesterol concentration (p<0.05)., Meat cholesterol concentration , basal diet , 2% seamustard ,0,
edin,969,3491047,Significantly increased,Short-term program adherence was greater in WB compared to C (p<0.012) after 3 months., Short-term adherence to the program at 3 months , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,1046,4748685,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = â9 mmHg; p = 0.03; 95 % CI = [â17.29, â0.71]), LDL (pseudo-median of the differences = â7.9 mg/dl; p = 0.04; 95 % CI = [â18.5, â0.5]) and triglyceride values (pseudo-median of the differences = â12.5 mg/dl; p = 0.04; 95 % CI = [â26, â0.5]) in the intervention group, while no such changes could be observed in the control group.", Triglyceride levels , Standard care , CAPSYS system ,0,
edin,1089,4082484,Significantly increased,"On the other hand, the consumption of the curry meal increased FMD from 5.2âÂ±â2.5% to 6.6âÂ±â2.0% (Pâ=â0.001), and the postprandial FMD after the curry meal was higher than that after the control meal (Pâ=â0.002).", postprandial FMD , spice-free control meal , single serving of curry meal ,0,
edin,1009,5003313,Cannot tell based on the abstract,, Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,1009,5003313,No significant difference,Also the results of t-test show that the changes in the severity of RLS symptoms before intervention and after 4 weeks were not statistically meaningful between intervention and control groups., Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,980,5619630,Cannot tell based on the abstract,, Relapse rates , Medication only , Medication plus exercise ,0,
edin,980,5619630,No significant difference,"Relapse rates were also recorded via subjective reports and as a measured increase of >50% from baseline HRSD scores (Neumeister et al, 1997). In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisherâs exact test: one-tailed, P = 0.07; two-tailed, P = 0.14).", Relapse rates , Medication only , Medication plus exercise ,0,
edin,1195,3743641,Cannot tell based on the abstract,, vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1195,3743641,Significantly decreased,"Additionally, treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P < 0.001) and a greater improvement in the womenâs most bothersome vulvovaginal atrophy symptoms (P < 0.05) compared with placebo (Figure 4).19", vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1202,4280954,Cannot tell based on the abstract,," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,1202,4280954,Significantly increased,"Serum and liver TBARS, as indices of lipid peroxidation, were significantly increased in the DM group compared with those in the control group, while the addition of flaxseed or a combination of flaxseed and Î±-tocopherol to the high-fat diet of the hamsters with DM significantly decreased these two markers compared with those in the unsupplemented DM group."," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,993,3074545,Cannot tell based on the abstract,, Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,993,3074545,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.", Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,1250,5225191,Cannot tell based on the abstract,, GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1250,5225191,Significantly increased,"After evocation, participants who underwent the conditioning procedure with amitriptyline reported significantly more antidepressant-specific side effects than those who never received amitriptyline, even though both groups received a placebo.", GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1321,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (r = 0.61, p = 0.01).,In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2âÂ±â0.4âkg/m2; 27âÂ±â1.3 years, meanâÂ±âSEM) underwent 50âg OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions.", the 2-hour plasma ghrelin , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1306,5789132,Cannot tell based on the abstract,, The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1306,5789132,Significantly decreased,"The mean pain score using FRS scale for 26 gauge conventional syringe was found to be 3.25, whereas mean pain score for 30 gauge insulin syringe was found to be 1.35 (Table 1). The mean difference found was statistically significant (p = 0.05).", The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1293,3636800,No significant difference,"Although there were no significant differences in participantsâ quantitative feedback for the two delivery modalities, most participants reported preferring the native smartphone application (67%; n=16) and found it easier to use (71%; n=16). 33% of participants reported that they would be willing to complete mobile phone assessment for 5 weeks or longer.", the total quantitative feedback score , completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation , completing 6 days of assessment (four sets of questions per day) with a native smartphone application ,0,
edin,586,4819709,Cannot tell based on the abstract,, Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,586,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">15Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">28Â·7</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,1223,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1223,3917123,Significantly decreased,"ost-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1213,5397544,Cannot tell based on the abstract,, Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1213,5397544,No significant difference,There were no significant changes in Î±-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups (Tables IV and V)., Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1343,5320660,Cannot tell based on the abstract,, Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1343,5320660,No significant difference,Mean overall satiety score did not differ within or between groups (Pâ=â0.230)., Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1279,5928476,Significantly decreased,SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements., bulk-fill composite resinsâ bond strengths , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,724,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,724,2600646,No significant difference,Final mean Hb levels were 7.15 mmol/l Â± 1.07 for the DP treatment group and 6.79 mmol/l Â± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05)., mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,1238,5228611,Cannot tell based on the abstract,, quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1238,5228611,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had statistically significant declines in both measures of quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) at week 48 vs. increases in the baseline regimen group (Fig. 4)., quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1219,5741263,Significantly increased,"In contrast to the reported positive effects of training on writing size, the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group.", Stroke duration , Placebo , Amplitude training ,0,
edin,637,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,1243,3466198,Significantly decreased,The median vaginal and cervical pH was significantly lower 2 hours after application of Acidform and was associated with an increase in the bactericidal activity of CVL against E. coli., The median vaginal and cervical pH , hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1278,3585965,Cannot tell based on the abstract,, the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1278,3585965,No significant difference,"When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV).", the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1264,3933059,Significantly decreased,Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (7%; P = 0.013) and DBP (6%; P < 0.010).," Systolic blood pressure (SBP), diastolic blood pressure (DBP) ", baseline , Pomegranate juice (PJ) ,0,
edin,1304,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1304,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,No clinically meaningful interactions were observed when EG was co-administered with other commonly used medicinal products and no dose adjustment was recommended"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1285,4132637,No significant difference,"Regardless of revascularization or not, ticagrelor consistently reduced the primary outcome (HR 0.86 vs. 0.85, interaction P = 0.93), and all-cause death (HR 0.75 vs. 0.73, interaction P = 0.89) with no significant increase in overall major bleeding.", All-cause death , clopidogrel , ticagrelor ,0,
edin,1269,3655855,Cannot tell based on the abstract,," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1269,3655855,No significant difference,"<td align=""left"">CRP (nmol/L)</td><td align=""center"">20.7</td><td align=""left"">21.8</td><td align=""center"">17.3</td><td align=""left"">18.7</td><td align=""left"">+0.12</td><td align=""left"">0.34</td><td align=""left"">0.53</td>,The effects of supplementation on components of the metabolic syndrome, plasma lipids, vascular measures, and cytokines are shown in TableÂ 3. The daily treatment dose of 1.7Â g of O3 for four weeks had no effect on any of these measures compared to the safflower placebo. Not shown are BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10, all of which also showed no effect."," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1267,4709985,Cannot tell based on the abstract,, would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,1267,4709985,Significantly increased,"The role of educational status was examined in response these questions and we found women with tertiary education would have liked more information on acupuncture (pâ<â0.009), no other associations were found.", would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,702,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,702,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25â1.69) and SU (37.9%; RR 1.45, 95% CI 1.22â1.73) (Table 2).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,1342,5320660,Significantly decreased,"Within the HAM-RS2 group, the area under the curve (AUC) glucose (Pâ=â0.028), AUC leptin (Pâ=â0.022), and postprandial 120-min leptin (Pâ=â0.028) decreased independent of changes in body composition or overall energy intake at the end of 6Â weeks."," glucose, AUC leptin, and postprandial 120-min leptin ", muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1301,3924124,Cannot tell based on the abstract,, CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1301,3924124,Significantly increased,"Significant (P < 0.05) interaction was observed for the secondary outcome measure CD4/8, which was used to represent participants' immunological function.,Significant (P < 0.05) effects were observed in CD4+ and CD4/8, which were maintained in the high adherence group, but tended to decrease in the low adherence and control groups", CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1310,3258678,Significantly decreased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., hippocampus volume (HV) change , 78-week treatment with placebo , 78-week treatment with tramiprosate 150 mg BID ,0,
edin,1331,4716419,No significant difference,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44)."," Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) ",  intravenous cyclophosphamide (CYC) 0.5â1?g/m2 monthly , enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months ,0,
edin,820,5294349,Cannot tell based on the abstract,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,0,
edin,820,5294349,Invalid Prompt,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,1," No datasets of 3D coordinates or anything similar was mentioned in results, discussion or conclusion section of the article. "
edin,768,3108665,Cannot tell based on the abstract,, Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,768,3108665,Significantly decreased,"Finally, with the help of logistic regression we concluded that the patients who did not receive somatostatin (control group) had a 6.2 times higher probability of developing complications than the treatment group.", Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,1292,5551214,Cannot tell based on the abstract,," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1292,5551214,Significantly decreased,"There was a significant interaction effect between pre- to post-test change in CARS2 scores and intervention condition (F(1, 22) = 7.219, p = 0.013, r = 0.5).,Whilst the control group had the same mean CARS2 scores at pre-test and post-test (42.61), the intervention groupâs mean score was significantly lower at post-test (40.05) than at pre-test (40.95) (Figure 1)."," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance.", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01),", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1255,4864053,Cannot tell based on the abstract,, mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1255,4864053,Significantly decreased,"For a composite gray matter region, a oneâsample tâtest showed that lâdopa was associated with an 11% mean decrease in [11C]Ro15â4513 BP (tÂ =Â â2.29, 9 degrees of freedom, PÂ =Â 0.048).", mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1298,5951568,Cannot tell based on the abstract,, Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1298,5951568,No significant difference,Overall pain scores between the intervention (20.91Â±2.33mm) and non-intervention group (25.30Â±2.44mm) in the NCS cohort did not differ significantly (p = 0.15)., Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1271,4401879,No significant difference,"Serumlevels of fasting blood sugar, insulin and homeostatic model assessment of insulin resistance slightly decreased in zinc group, but these changes were not statistically significant."," fasting blood sugar, insulin and homeostatic model assessment of insulin resistance ", placebo for eight consecutive weeks , 30mg/day zinc gluconate for eight consecutive weeks ,0,
edin,734,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,734,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,1226,4996255,Significantly increased,"Across the two Phase IIIa active comparator studies, patients consistently stated a preference for the Elliptaâ¢ DPI over HandiHalerÂ® regarding the number of steps to use (59% vs 17%), time taken to use (62% vs 14%), and ease of use (63% vs 15%) regardless of which inhaler contained active drug."," the number of steps to use, time taken to use and ease of use ", HandiHalerÂ® , Elliptaâ¢ DPI ,0,
edin,1240,5228611,Cannot tell based on the abstract,, HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1240,5228611,No significant difference,E/C/F/TAF plus DRV was noninferior to baseline regimens for the primary outcome (HIV-1 RNA <50 copies per mililiter at week 24; FDA-snapshot algorithm) using the full analysis set (96.6% vs. 91.3%; difference 5.3%; 95.001% CI: â3.4% to 17.4%) (Fig. 3)., HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1265,3933059,No significant difference,"However, changes in FMD (20%) as well as circulating levels of CRP, ICAM-1, VCAM-1, E-selectin, and IL-6 did not reach statistical significance (P = 0.172).", flow-mediated dilation (FMD) , baseline , Pomegranate juice (PJ) ,0,
edin,1312,3258678,Significantly increased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., Alzheimer Disease Assessment Scale â cognitive subscale (ADAS-cog) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1281,4132637,Cannot tell based on the abstract,, The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1281,4132637,Significantly decreased,"The incidence of the primary composite endpoint was reduced with ticagrelor vs. clopidogrel (10.0 vs. 12.3%; HR 0.83; 95% CI = 0.74â0.93; P = 0.0013) (see Supplementary material online, Figure S1A).", The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1319,5494586,Cannot tell based on the abstract,, glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1319,5494586,Significantly decreased,"As for the comparison among the incremental peak values of glycemia (Figure 1(a), 1(b), and 1(c)), the repeated measures ANOVA with Greenhouse-Geisser correction resulted significant (p < 0.001) and the Tukey-Kramer post hoc test revealed that B1 (36.2âÂ±â3.8âmg/dL), B2 (19.6âÂ±â2.9âmg/dL), and B3 (27.3âÂ±â4.0âmg/dL) had significantly smaller glucose incremental peaks than A (55.9âÂ±â6.1âmg/dL) with p values associated to such post hoc comparisons that were p = 0.04, p < 0.001, and p = 0.002, respectively.", glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1291,5551214,Cannot tell based on the abstract,, the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,1291,5551214,No significant difference,"No significant Spearmanâs correlations were found between change and baseline scores on the CARS2, nor between change and baseline scores on the Hyperactivity subscale of the ABC-C.,The mixed ANOVA for the Irritability subscale of the ABC-C found no significant main or interaction effects (Table 2).", the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,710,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,710,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32â11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,1253,3172326,Significantly increased,The interval time for the first analgesic request was 23.1 Â± 6.7 minutes for the case group and 18.1 Â± 7.3 minutes for the control (P = 0.02)., The interval time for the first analgesic request , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,548,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,548,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1," Health care workers with IgG are only mentioned in methods section where groups are explained. In the results section IgG is not mentioned, there only higher risk of infection for workers working on the frontline"
edin,1340,4012222,Cannot tell based on the abstract,, Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1340,4012222,No significant difference,"Global performance status and STS appeared somewhat better, but these changes did not achieve statistical significance (Fisherâs exact test p =â0.15 comparing categories of PS; mean reduction in STSâ=ââ1.2s, Pâ=â0.3).", Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1320,5494586,Cannot tell based on the abstract,,  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1320,5494586,Significantly decreased,"All three commercial breakfasts showed somewhat smaller insulin excursions with respect to the one elicited by glucose administration (Figure 2(a), 2(b), and 2(c)).",  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1280,5928476,No significant difference,"SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements. However, no statistically significant differences were observed between bulk-fill composite resins values and calcium silicate cement values.", bulk-fill composite resin values and calcium silicate cement values , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,1245,3466198,Significantly decreased,"While there was no increase in inflammatory cytokines or chemokines, CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, were significantly lower following Acidform compared to HEC placebo gel application."," CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, ", hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1335,5673730,Significantly decreased,Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021)., numbers of babies were delivered after 38 weeks of pregnancy , insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B) , oral metformin 500 mg TDS (Group-A) ,0,
edin,1325,5236513,Significantly increased,"At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as ânormalâ compared to Placebo (respectively 3.13 Â± 1.197 a.u. vs 2.58 Â± 1.020 a.u., P = 0.0003).", stool consistency , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
edin,1237,5228611,Cannot tell based on the abstract,, eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1237,5228611,No significant difference,There were no differences between the 2 groups in median changes from baseline in eGFR (week 48: +7.4 mL/min vs. +3.9 mL/min; P = 0.18)., eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1344,5320660,Cannot tell based on the abstract,, The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1344,5320660,No significant difference,The mean score for the question âhow full do you feel?â in the HAM-RS2 group increased from baseline to the end of the study and approached significance (Pâ=â0.058) (data not shown)., The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1252,3172326,Significantly decreased,"For all of the evaluated times, the VAS score was significantly lower in the ketamine group compared to the control.", visual analogue scale (VAS). , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,1287,4132637,Significantly increased,"Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95â1.19), but ticagrelor was associated with an increase in non-CABG major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI = 1.05â1.56).", non-CABG-related major bleeding , clopidogrel , ticagrelor ,0,
edin,1233,5506592,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (differenceÂ âÂ 0.05, 95% CIca â0.100 to â0.010).", the proportion of households who purchased anti-mosquito products in the last month , baseline , education and mobilisation activities ,0,
edin,654,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question 
edin,1333,3917204,Cannot tell based on the abstract,, Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,1333,3917204,No significant difference,Clinical improvement was noticed in both moderately deep pocket sites and deep pocket areas. But comparison of groups showed them to be statistically nonsignificant [Tables 4 and 5]., Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,791,125315,Cannot tell based on the abstract,, The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,791,125315,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343)., The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,1303,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1303,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,The calculated pharmacokinetic parameters were closely related to previous studies conducted in white German subjects using 25âmg EG. The insignificant difference in ANOVA statistical results (TableÂ 2) of the pharmacokinetic evaluation in Egyptians and white German subjects13, 15, 20, 38 suggests that no dose adjustment should be considered with administration of 25âmg EG to Egyptian population.Table 2"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1225,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1225,3917123,Significantly increased,"Post-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1364,4365564,Cannot tell based on the abstract,, Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1364,4365564,No significant difference,"The rate of approach-related complications in all 304 patients was 9.9% (30/304) and was similar between the 2 groups, with 9.8% (20/205) in the investigational group and 10.1% (10/99) in the control group (Table 2).,<td align=""left"" colspan=""1"" rowspan=""1"">Retrograde ejaculation, no. (%)<xref ref-type=""table-fn"" rid=""TF0002"">a</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">3 (3.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">3 (5.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">.515</td>", Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1471,4367028,Cannot tell based on the abstract,, PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1471,4367028,Significantly increased,Again PACU stay was longer (P < 0.05) in TBG >30Â° group compared to TBG <30Â° group [Table 6]., PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1420,2361654,Cannot tell based on the abstract,, colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1420,2361654,Significantly increased,"Compared with the conventional arm, clearly more colposcopy referrals were made in the hrHPV screening arm (RR 1.51, CI 95% 1.03â2.22).", colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1498,3846239,Significantly decreased,The analgesic requirement was significantly lower in the B+D group compared with the B group., The analgesic requirement , bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1515,2361520,Cannot tell based on the abstract,, time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1515,2361520,No significant difference,The time to disease progression from randomisation to after chemotherapy was similar in the immediate- and delayed-treatment groups for both studies (Table 3), time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1428,5553001,Cannot tell based on the abstract,, PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1428,5553001,No significant difference,"Table 1
Baseline characteristics of parents.,<td colspan=""1"" rowspan=""1""><break></break></td><td colspan=""1"" rowspan=""1"">PCL-C<sup>j</sup></td><td colspan=""1"" rowspan=""1"">49.1 (10.3)</td><td colspan=""1"" rowspan=""1"">51.5 (9.4)</td><td colspan=""1"" rowspan=""1"">46.6 (10.7)</td><td colspan=""1"" rowspan=""1"">.06</td>", PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1378,3628658,No significant difference,There was not statistical significance on union time and Harris values in the two position groups., Harris hip values and union time of fractures , Supine position , Lateral decubitus position ,0,
edin,1369,5311860,Cannot tell based on the abstract,," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1369,5311860,No significant difference,"However, when the term for âwatchful waitingâ is excluded from public health response, the results were not significant (TableÂ 5).Table 5"," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1380,4659198,Significantly decreased,"On the third day, the massage group showed significantly higher defecation frequency (pâ=â0.045) and significantly lower bilirubin levels (pâ=â0.03) compared with the control group.", Bilirubin levels after 3 days , Phototherapy only , Phototherapy plus massage ,0,
edin,1459,4600230,Cannot tell based on the abstract,, a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1459,4600230,Significantly increased,"A significantly higher number of participants from the intervention group passed a pre-established pass/fail level of 50.0% in OSAUS score compared with the control group (85.7% vs 8.3%, respectively; P < 0.001).", a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1507,5850185,Significantly increased,he subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=â1.54; P=0.004) than those in the unilateral TENS+TOT group., the TUG completion time at A1 and A2 , baseline , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
edin,1372,5285426,Significantly increased,Composite male urological and sexual function score changes from baseline were better in the robotic cohort (pÂ <Â 0.001)., Male sexual function scores , Laparoscopic surgery , Robotic surgery ,0,
edin,1412,5578640,Significantly increased,The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21)., The ESAS QoL-score after 1 month , untreated (control) , vitamin D 4000 IE/day ,0,
edin,1482,4881089,Cannot tell based on the abstract,, prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1482,4881089,No significant difference,McNemar test showed no significant difference in the prevalence rates of musculoskeletal symptoms in all regions before and after intervention., prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1525,4092926,No significant difference,"There was no influence of the treatments on any of the mean values of the evaluated measures (p>0.05): 21.78 kg (body weight at slaughter), 8.65 kg (hot carcass weight), 8.59 kg (cold carcass weight), 40.27% (hot carcass yield), 39.20% (cold carcass yield), 7.73 cm2(rib eye area), 46.74 cm (carcass outer length), 45.68 cm (carcass internal length), 36.92 cm (leg length), 26.04 cm (leg perimeter), 48.66 cm (hind perimeter), 58.62 cm (thoracic perimeter), 0.20 (carcass compactness index), 68.48% (total muscle of the leg), 2.79% (total leg fat), 55.19% (subcutaneous leg fat), 28.82% (total bone), 81.66 g (femur weight), 14.88 cm (femur length), 0.38 (leg muscularity index), 2.53 (muscle:bone ratio) and 33.42 (muscle:fat ratio).", goats body weight at slaughter , soybean meal , sunflower cake ,0,
edin,1511,4134501,Cannot tell based on the abstract,, Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1511,4134501,No significant difference,"At the end of cycle 3, 10 (67%) and 7 (58%) patients in Arms A and B, respectively, had achieved a partial response, whereas an additional 4 patients in each arm (27% and 33%, respectively) had stable disease.", Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1497,4274342,Cannot tell based on the abstract,, pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1497,4274342,No significant difference,"There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups. Two women had bladder prolapse (one ospemifene participant and one placebo participant), and one ospemifene participant had a report of cystocele.", pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1512,2361520,No significant difference,"Median survival was not significantly better with immediate treatment (median 13.0 vs 11.0 months; hazard ratio, 1.15; 95% confidence interval (CI) 0.79â1.72; P=0.49).", Median survival , receive delayed treatment , receive immediate treatment ,0,
edin,1261,5414544,Significantly increased,"he rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratioâ=â1.54, Pâ<â0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.", The rate of HBsAg positivity , Uganda , Zimbabwe ,0,
edin,1501,2627861,Cannot tell based on the abstract,, maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1501,2627861,Significantly decreased,"In the intent-to-treat analysis (n = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (p = 0.004) (Table 2).", maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1493,5021748,No significant difference,"he initial bolus heparin dosages required to produce an ACT 15Â min after the initial bolus that was identical to the control (333Â Â±Â 32Â s) were 120 U/kg (318Â Â±Â 29Â s) and 130 U/kg (339Â Â±Â 43Â s) for dabigatran, 130 U/kg (314Â Â±Â 31Â s) for rivaroxaban and 130 U/kg (317Â Â±Â 39Â s) for apixaban.,The NOAC groups required significantly larger doses of total heparin than the warfarin group.,The results of the comparison with warfarin (the control) indicated that dosages of 120 or 130 U/kg for dabigatran, and 130 U/kg for rivaroxaban and apixaban, were adequate initial heparin dosages.", heparin dosages required to produce an ACT 15 min after the initial bolus  that was identical to the control (110U/kg) , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1473,4222592,Significantly decreased,"ompared to the C test meal, the AA test meal increased satisfaction by 23% (P=0.05) and decreased the desire to eat by 28% (P=0.04) for the AUC(0-5h).", desire to eat  for the AUC(0-5h) , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Added (AA) ,0,
edin,1461,4600230,Cannot tell based on the abstract,, knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1461,4600230,No significant difference,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095).", knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1453,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1453,3406743,No significant difference,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.,The UCG did not change between baseline and follow-up; 75% of women in this group reported moderate physical activity at baseline, and 77% at follow-up.", engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1495,4274342,Cannot tell based on the abstract,, vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1495,4274342,No significant difference,"aginal bleeding or spotting was reported in 10 of 851 women (1.2%) with an intact uterus in the ospemifene 60 mg/day group (incidence rate, 2.17 per 100 patient-years) and in 5 of 543 women (0.9%) in the placebo group (incidence rate, 2.72 per 100 patient-years; P = 0.7; Table 3).", vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1499,3846239,Significantly decreased,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain values were significantly lower in the B+D group than in the B group."," At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores ", bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1444,5610684,Cannot tell based on the abstract,," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1444,5610684,No significant difference,"There were no significant condition differences for tension F(1, 91) = 1.56, p = 0.21, 95% CI [â0.29, 1.25], Î·2 = 0.02; anxiety F(1, 88) = 0.004, p = 0.95, 95% CI [â1.01, 0.95], Î·2 = 0.00; or well-being F(1, 91) = 0.33, p = 0.57, 95% CI [â0.49, 0.90], Î·2 = 0.004."," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1416,5456350,Cannot tell based on the abstract,, wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1416,5456350,No significant difference,"There were no significant differences in responses to survey items (pertaining to desire to receive a DEKA Arm, self-rated skill in use, perception of weight, ratings of socket comfort, or preferences for DEKA Arm over personal prosthesis) administered at the end of Part A and the end of Part B (Table 2).", wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1435,5336430,Significantly increased,"At 8Â weeks after the end of treatment, CCC was significantly higher with 5-FU 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (OR) 3.9 (95% CI) 1.7, 8.7; PÂ =Â 0.0006].", The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint) , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1523,4107254,Significantly increased,"Centers admitting â¥ 200 patients/year (70.7% vs. 45%; p = 0.039), and those with stroke units (95 vs. 20; p = 0.031) were more willing to join a randomized trial evaluating any of the methods.", willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients , centers without stroke unit , centers with stroke unit ,0,
edin,1430,5566825,Cannot tell based on the abstract,, total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1430,5566825,Significantly decreased,"Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (P < 0.01) and the proportionate difference was about 2 times (1.91) [Figure 3].", total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1503,5854362,Cannot tell based on the abstract,, anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1503,5854362,No significant difference,"Our first and primary hypothesis, that CBM-I would result in reduced anxiety and depressive symptoms compared to Placebo, was not confirmed, as no significant Condition x Time interactions were observed for SCARED and CDI scores.", anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1522,4107254,Cannot tell based on the abstract,, Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1522,4107254,No significant difference,"Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, p = 0.05).", Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1494,4274342,Cannot tell based on the abstract,, The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1494,4274342,Significantly increased,"The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â¤ 0.001, Welchâs test) at all three evaluations.", The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1510,4134501,No significant difference,The safety profiles were similar between arms and treatment was well tolerated., The safety profiles , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1393,4599543,Significantly decreased,"Postoperative bleeding was significantly (P=0.042) less in the treatment arm (median, 300Â mL; interquartile range, 200 to 400Â mL) than in the control arm (median, 355Â mL; interquartile range, 250 to 600Â mL).", postoperative bleeding , received saline solution (placebo) , received fibrinogen concentrate ,0,
edin,1466,2837815,No significant difference,The Merle dâAubigne Postel score was the maximum of 18 points for all patients in both groups., The Merle dÃ¢â¬â¢Aubigne Postel score , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
edin,1374,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Hospital stay , Supine position , Lateral decubitus position ,0,
edin,1359,3842830,Significantly decreased,"The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (â0.99 hours, Pâ=â.003) and istradefylline 40 mg/day (â0.96 hours, Pâ=â.003) groups compared with the placebo group (â0.23 hours).", Daily OFF time , Placebo , Istradefylline 20 mg or 40 mg ,0,
edin,1452,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1452,3406743,Significantly increased,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.", engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1375,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Loss of blood during surgery , Supine position , Lateral decubitus position ,0,
edin,1496,4274342,Cannot tell based on the abstract,, endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1496,4274342,No significant difference,There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials., endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1441,5336430,Cannot tell based on the abstract,, DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1441,5336430,No significant difference,"<td align=""left"" colspan=""4"">DLQI total score</td>", DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1467,4367028,Cannot tell based on the abstract,, SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1467,4367028,No significant difference,"Baseline hemodynamic parameters like SBP, DBP, mean arterial pressure (MAP), pulse rate and also hemoglobin were found to be comparable [Table 3] among two groups.,Head down tilt was associated with a rising trend in SBP and DBP which was higher in TBG >30Â° than TBG <30Â° group however the results were not statistically significant [Table 4].", SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1401,5766333,Cannot tell based on the abstract,, the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1401,5766333,Significantly decreased,"On the other hand, the minimum pulse rate was significantly lower in the Combination group than in the PF group (47 [34âââ61] bpm vs. 59 [36âââ72] bpm, P â<â0.001, median [range]),", the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1460,4600230,Cannot tell based on the abstract,," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1460,4600230,Significantly increased,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095)."," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1394,5724392,Cannot tell based on the abstract,"Final model-based TCD velocities (mean Â± standard error) on Standard versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1394,5724392,Significantly increased,"The final model-based TCD velocities (mean Â± standard error) on the Standard Arm versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and a post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1456,3406743,Significantly increased,A culturally tailored adaptation of the WISEWOMAN program that used community health workers significantly improved both self-reported readiness to engage in physical activity and vigorous physical activity among low-income Latinas., readiness to engage in vigorous physical activity , baseline , enhanced intervention (EIG) ,0,
edin,1419,5456350,Cannot tell based on the abstract,, rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1419,5456350,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;DEKA arm function</td><td align=""center"" colspan=""1"" rowspan=""1"">31</td><td align=""center"" colspan=""1"" rowspan=""1"">5.3 (1.4)</td><td align=""center"" colspan=""1"" rowspan=""1"">17</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (1.0)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">4.7 (1.6)</td><td align=""center"" colspan=""1"" rowspan=""1""><bold>0.0468</bold></td>,<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;External Battery Life</td><td align=""center"" colspan=""1"" rowspan=""1"">32</td><td align=""center"" colspan=""1"" rowspan=""1"">5.7 (1.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">18</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (0.8)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">5.5 (1.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.9928</td>", rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1470,4367028,Cannot tell based on the abstract,, Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1470,4367028,Significantly increased,Nitroglycerine and fentanyl use in TBG >30Â° group was higher and statistically significant (P < 0.05) when compared with TBG <30Â° [Table 6]., Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1370,5285426,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.", Urological function scores in females , Laparoscopic surgery , Robotic surgery ,0,
edin,1478,4673066,Cannot tell based on the abstract,, performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1478,4673066,Significantly increased,"Schema-based instruction was associated with increased performance on the diagnostic performance test (64â%âÂ±â22 vs 44â%âÂ±â25, pâ<â0.001).", performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1383,4659198,Cannot tell based on the abstract,, Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1383,4659198,No significant difference,"TableÂ 1 shows the medical characteristics of participating neonates. We observed no significant differences between the two groups in terms of type of feeding, gestational age at birth, body weight at birth, body weight on the date of admission, phototherapy duration, or physical weight loss.Table 1", Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1485,4881089,Cannot tell based on the abstract,, any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1485,4881089,No significant difference,Table 5 also shows that there was no significant difference in any of the scales of the Thai version of the COPSOQ questionnaire before and after intervention in the control group., any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1526,4092926,Cannot tell based on the abstract,," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1526,4092926,No significant difference,Weights and carcass yields as well as rib eye area showed no differences (p>0.05) with the substitution of soybean meal by sunflower cake.," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1434,5566825,Cannot tell based on the abstract,, CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1434,5566825,Significantly increased,Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [Table 7]., CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1492,5021748,Cannot tell based on the abstract,, protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1492,5021748,No significant difference,"No significant differences in protamine usage for haemostasis were found among the control and three NOAC groups (control, 13Â Â±Â 20; dabigatran, 26Â Â±Â 23; rivaroxaban, 25Â Â±Â 25; apixaban, 28Â Â±Â 28Â mg).", protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1377,3628658,Significantly decreased,"he hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Surgery time , Supine position , Lateral decubitus position ,0,
edin,1440,5336430,Cannot tell based on the abstract,, the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1440,5336430,No significant difference,"No statistically significant differences were observed between the study arms for the TSQM convenience (70.7 and 71.2, respectively) and side effect (92.4 and 96.4, respectively) domain scores.", the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1365,4365564,Significantly increased,There was a higher rate of superficial wound infection in the investigational group but no deep wound infections in either group., Rate of superficial wound infection , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1355,3179725,Significantly increased,"<td align=""left""><bold>After four treatments</bold></td><td></td><td></td><td></td>", Dyspnea improvement , Sham chest wall oscillation treatment , Active chest wall oscillation treatment ,0,
edin,1637,5420386,Significantly increased,"<td colspan=""5"">5D-ASC scale</td>"," ratings of blissful state, insightfulness, and changed meaning of percepts ", 100&amp;amp;nbsp;ÃÂ¼g dose of LSD , oral administration of 200 ÃÂ¼g LSD ,0,
edin,1623,3719224,Significantly increased,"Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 Â± 1.38 vs. 3.53 Â± 1.61), perceived susceptibility (14.05 Â± 1.51 vs. 12.37 Â± 2.11), and perceived benefits (28.41 Â± 2.14 vs. 27.51 Â± 3.05), at follow-up time after 3 months (P < 0.05)."," the variables, knowledge ", received just routine education , received educational intervention plus routine education ,0,
edin,1551,4396724,Cannot tell based on the abstract,, Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1551,4396724,No significant difference,"Maximal heart rate achieved at the end of the graded exercise test, body mass, and waist circumference did not change significantly from baseline to one-month follow-up in either HIIT or MICT (P's > 0.05).", Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1632,5420386,No significant difference,"On the MEQ, 200Â Î¼g LSD induced mystical experiences that were comparable to those in patients who underwent LSD-assisted psychotherapy but were fewer than those reported for psilocybin in healthy subjects or patients.", Mystical Experience Questionnaire (MEQ) scores , placebo , oral administration of 100 and 200&amp;nbsp;ÃÂ¼g LSD ,0,
edin,1536,5941723,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5âmm penetration versus 1âmm skin press and 10âmm penetration versus 2âmm skin press.", Needle pain intensity , Placebo , Acupuncture ,0,
edin,1531,5343624,Cannot tell based on the abstract,, Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1531,5343624,No significant difference,"The radiologic analysis of the BO graft revealed volumetric reduction in all patients.,The volume reduction of the BO graft was not significant.,The radiologic analysis of the NB graft revealed volumetric reduction in all patients.,The volume reduction of the NB graft was not significant.", Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1588,3810136,Cannot tell based on the abstract,, Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1588,3810136,Significantly decreased,"In addition, lower free IGF-1 levels were measured in the T-HS/Ctr group than PF group at day 4 and it reached statistical difference by day 6 (p<0.01), indicating that the depressed IGF-1 expression was sustained 6 days following T-HS after eliminating the interference of reduced food intake.", Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1667,5017045,Cannot tell based on the abstract,, number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1667,5017045,No significant difference,There were no significant differences in the number of operated patients between the two groups (pâ=â0.432)., number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1563,3094237,Cannot tell based on the abstract,, Adverse side effects , Placebo , L-lysine ,0,
edin,1563,3094237,No significant difference,"urthermore, the L-lysine treatment was not found to induce any adverse side effects including extrapyramidal effects.", Adverse side effects , Placebo , L-lysine ,0,
edin,1600,5434251,Cannot tell based on the abstract,, PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1600,5434251,No significant difference,"<td colspan=""2"" rowspan=""1"">PTQ<sup>g</sup> (perseverative thinking), mean (SD)</td><td colspan=""1"" rowspan=""1"">38.50 (10.97)</td><td colspan=""1"" rowspan=""1"">45.32 (9.95)</td><td colspan=""1"" rowspan=""1"">t<sub>35</sub>=â1.98; <italic>P</italic>=.06</td>", PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1561,5916905,No significant difference,"After BM-intervention, fat mass increased (+1.0âÂ±â1.8âkg; pâ<â0.05) and postprandial insulin sensitivity tended to decrease (ÎMatsudaISI: â0.89âÂ±â2.3; pâ=â0.06).,Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ>â0.05).",  Insulin sensitivity after meals , Orange juice intake with each meal (WM)  , Orange juice intake in-between meals (BM) ,0,
edin,1591,2714198,No significant difference,No difference in survival time was observed across the different groups., Survival time , Control groups , Suture groups ,0,
edin,1609,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Pregnancy , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1574,5791393,Cannot tell based on the abstract,, Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1574,5791393,No significant difference,"There was also no significant difference in the post-operative hospital stay between the groups, both in total and separately in women and in men.", Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1564,3094237,Significantly decreased,"<td align=""left""><underline>PANSS</underline></td><td></td><td></td><td></td><td></td><td></td>", Symptom severity by PANSS measure , Placebo , L-lysine ,0,
edin,1583,5642191,Cannot tell based on the abstract,, Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1583,5642191,No significant difference,No differences in baseline characteristics were found between the three intervention groups (Table 1)., Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1575,5791393,No significant difference,"Catheterisation does not influence: the number of additional doses of ketoprofen and pethidine administered during the 1st day after the operation, the duration of hospitalization, the occurrence of fever, significant bacteriuria, the postoperative acute urinary retention and the post-void residual urine volume.", Fever , Without catheter (group I) , With catheter (group II) ,0,
edin,1666,5017045,Cannot tell based on the abstract,, The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1666,5017045,Significantly increased,"In the subgroup analyses restricted to patients who required casting, we observed a significantly longer mean consultation time in the RMC group (29.0Â min) compared to the UNN group (22.6Â min, pâ=â0.0063).", The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1672,2941605,Cannot tell based on the abstract,, Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1672,2941605,Significantly increased,Skin reaction was also lower in the Vinorelbine arm when compared with the other arm., Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1630,3640164,Cannot tell based on the abstract,," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1630,3640164,Significantly increased,"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time were shorter in the spinal anesthesia group than in the PSNB group (P < 0.01)."," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1604,4335741,Significantly decreased,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences, but vocal cords were significantly more patent in group R than those in group A (P = 0. 028).", Vocal cords patency , Remifentanil , Alfentanil ,0,
edin,1675,4737200,Cannot tell based on the abstract,, second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1607,4335741,Cannot tell based on the abstract,, Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1607,4335741,No significant difference,"As shown in Table 3, the scores for ease of laryngoscopy (A), jaw relaxation (C), and limb movement (D) did not differ significantly between the two groups (Mann-Whitney test), but vocal cord patency (B) in group A was significantly higher than that in remifentanil group (P = 0. 028).", Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1611,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Live birth rate , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1550,4396724,Cannot tell based on the abstract,, Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1550,4396724,No significant difference,"There were no main effects for group or group by time interactions for these fitness parameter variables, indicating that there were no differences in the degree of change experienced between HIIT and MICT over time.", Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1658,2291328,Cannot tell based on the abstract,, hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1658,2291328,No significant difference,"There was a non-significant increase in the number of patients having a hospitalization for worsening CHF in the bisoprolol-first group compared with the enalapril-first group (63 vs 51 patients, respectively, HR = 1.25 [0.87â1.81], p = 0.23).", hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1597,2911596,Cannot tell based on the abstract,, HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1597,2911596,Significantly increased,"However, HR values were significantly different in SEVO and ISOF groups 70.6 Â± 13.0 versus 64.9 Â± 11.8, (P < .01), respectively (Figure 2).", HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1608,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Fertilization , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,621,1852268,Cannot tell based on the abstract,, obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,621,1852268,No significant difference,"At the primary efficacy endpoint 2â4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillinâtazobactam were cured (95% confidence interval for the difference, adjusting for strata, â4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,1676,4737200,Cannot tell based on the abstract,, mobility , control condition , barefoot conditions ,0,
edin,1676,4737200,No significant difference,There was no difference in the mobility or barefoot conditions in comparison to the control condition., mobility , control condition , barefoot conditions ,0,
edin,1655,2291328,Cannot tell based on the abstract,, heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1655,2291328,Significantly increased,Bisoprolol produced a significant reduction in heart rate associated with a non-significant increase in peak oxygen consumption., heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1601,5434251,Cannot tell based on the abstract,, SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1601,5434251,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1571,4924222,No significant difference,"After adjustment for baseline measurements there was no time by treatment effect for central systolic or diastolic BP, AIx or cfPWV.", Augmentation index (AIx) , Usual diet ," Increased intake of fruits, vegetables and dairy ",0,
edin,1663,3489577,Significantly decreased,"Total-, LDL-cholesterol and waist circumference decreased significantly in the oat group compared to the control.", total cholesterol and LDL-C  , 100 grams of wheat flour-based noodles , 100 grams of instant oat cereal ,0,
edin,1647,5498096,Cannot tell based on the abstract,, pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1647,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1578,5074260,Cannot tell based on the abstract,, Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1578,5074260,Significantly decreased,"At 26âweeks, 77.6% of patients receiving IDeg and 35.5% of those receiving placebo had achieved an HbA1c level <7.0% (<53âmmol/mol); the likelihood of achieving HbA1c <7.0% was significantly higher for participants in the IDeg addâon group [odds ratio 7.79 (95% CI 4.57; 13.27); pâ<â0.0001].", Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1598,5434251,Cannot tell based on the abstract,, Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1598,5434251,No significant difference,"<td colspan=""1"" rowspan=""1"">Number of exercises practiced</td><td colspan=""1"" rowspan=""1"">7.88 (4.92)</td><td colspan=""1"" rowspan=""1"">10.06 (6.80)</td><td colspan=""1"" rowspan=""1"">62.67 (61.64)</td><td colspan=""1"" rowspan=""1"">48.71 (44.28)</td><td colspan=""1"" rowspan=""1""><italic>t</italic><sub>30</sub>=â0.72</td><td colspan=""1"" rowspan=""1"">.48</td><td colspan=""1"" rowspan=""1"">0.25 (â0.45 to 0.96)</td>,The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1679,4737200,Cannot tell based on the abstract,, knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1679,4737200,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot â4.3%, pâ=â0.023; typical wedge â7.95%, pâ<â0.001; supported wedge â5.5%, pâ<â0.001).", knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1580,5074260,Cannot tell based on the abstract,, Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1580,5074260,Significantly increased,"The number of patients experiencing confirmed hypoglycaemia during randomized treatment was higher with IDeg (17.3%) than with placebo (4.7%; Table S3, Supporting Information).", Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1674,4737200,Cannot tell based on the abstract,, early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1674,4737200,Significantly decreased,"When we examined the effects of the conditions on measures of medial loading (Tables 1 and 2, Fig. 3), we found that barefoot walking had the greatest effect on early stance peak EKAM, lowering it by â7.6% (pâ<â0.001 vs. control shoe).", early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1665,5017045,Cannot tell based on the abstract,, The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1665,5017045,No significant difference,The mean consultation duration was not significantly different between the groups (pâ=â0.60)., The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1631,3640164,Cannot tell based on the abstract,, he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1631,3640164,No significant difference,"The anesthesia-related side effects in the spinal anesthesia group were hypotension, bradycardia, shivering, vomiting, postoperative headache, and urinary retension, occurring in 15%, 10%, 5%, 5%, 10%, and 20% of patients, respectively. There was no incidence of side effects in the PSNB group, but it was not statistically significant.", he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1554,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 4.5 MIU dose ,0,
edin,1648,5498096,Cannot tell based on the abstract,, pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1648,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1656,2291328,Cannot tell based on the abstract,," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1656,2291328,Significantly decreased,"Bisoprolol significantly reduced cardiovascular mortality (HR: 0.71 [0.56â0.9]), sudden cardiac death (HR: 0.56 [0.39â0.80]), hospital admission (HR: 0.80 [0.71â0.91]), and hospital admission for worsening heart failure (HR: 0.64 [0.53â0.79]) compared with placebo."," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1584,5642191,Cannot tell based on the abstract,, SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1584,5642191,No significant difference,"There were no differences in any of the SDQ change scores from pre to post between the fish and meat or fish and supplement group, neither before nor after adjusting for the participantsâ baseline scores or baseline and compliance scores (Table 2).Table 2.", SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1555,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 7.5 MIU dose ,0,
edin,1636,5420386,Cannot tell based on the abstract,, all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1636,5420386,Significantly increased,"<td colspan=""5"">MEQ30</td>", all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1537,5941723,Cannot tell based on the abstract,, Severe adverse events , Placebo , Acupuncture ,0,
edin,1537,5941723,No significant difference,There were no critical adverse events., Severe adverse events , Placebo , Acupuncture ,0,
edin,1616,3430047,Cannot tell based on the abstract,, PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1616,3430047,Significantly decreased,"Supplemental opioid demand, PHS criteria and bupivacaine consumption were statistically significant, as, rate of IV opioid consumption, PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).", PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1649,2856148,Cannot tell based on the abstract,, acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1649,2856148,No significant difference,"No significant difference between the two groups in duration of MV (6.20 Â± 5.20 days vs. 7.47 Â± 6.38 days, P > 0.05), duration of weaning (35.17 Â± 16.98 and 47.05 Â± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 Â± 4.79 and 10.80 Â± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.", acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1596,2911596,Cannot tell based on the abstract,," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1596,2911596,No significant difference,"MAC and SE values were similar in SEVO and ISOF groups before fentanyl boluses [0.74 Â± 0.12 versus 0.77 Â± 0.17, (P = .32) and 43.5 Â± 8.1 versus 45.2 Â± 8.3, (P = .47), resp.]."," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1573,5791393,Cannot tell based on the abstract,, Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1573,5791393,Significantly increased,It was confirmed that the catheterised patients had sensed more intensive pain than the non-catheterised subjects., Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1721,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1845,5599918,Cannot tell based on the abstract,, Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1845,5599918,Significantly increased,"Apart from the total administered dose of remifentanil and ephedrine, there were no significant differences among the 3 groups. The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P < 0.001, respectively).", Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1688,5362210,Cannot tell based on the abstract,, Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1688,5362210,Significantly decreased,"Correlation analyses of the following variables showed a significant correlation (p<0.05) between gestational age, birth weight, clinical chorioamnionitis, surfactant, mechanical ventilation, use of vasopressors, blood transfusions, and the burden of cerebral hypoxia within the 4th quartile on one hand and the composite outcome of severe brain injury or death on the other.,As described in the methods, centre, gestational age below 26 weeks, and intervention were forced-entry variables in the model. The following variables remained statistically significant: intervention (OR (95% CI) 0.29 (0.12â0.69; p = 0.003,)), gestational age below 26 weeks (3.33 (1.38â8.06; p = 0.007)), use of vasopressors (3.26 (1.26â8.44; p = 0.014)), and blood transfusion (2.97 (1.22â7.23; p = 0.016)).", Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1797,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1716,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1694,3600348,Significantly increased,Five (83%) of the patients who failed the SBT in ATC group were reintubated. This represented a higher negative predictive value for ATC of 83% than for PSV which was 56%, Causes of reintubation , Pressure support ventilation , Automatic tube compensation ,0,
edin,1844,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1745,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1745,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1809,3154934,Cannot tell based on the abstract,, Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1809,3154934,No significant difference,"There were no baseline differences between the children who had received neonatal VAS or placebo, continued to live in the study area and were met at follow-up (Table 1).", Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1753,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1753,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1766,4526979,Cannot tell based on the abstract,, Treatment categories change scores , Nonusers , Website users ,0,
edin,1766,4526979,No significant difference,"Summary change scores for treatment categories were also obtained. Between the intervention group and nonusers, there were minimal differences that did not reach statistical significance in core treatments (change scores 10.3% vs 4.7%, P=.17), adjunct treatments (change scores 3.1% vs 1.2%, P=.54), pharmacological treatments (change scores â1.7% vs â2.4%, P=.35), and nonpharmacological treatments (change scores 9.5% vs 4.0%, P=.29).", Treatment categories change scores , Nonusers , Website users ,0,
edin,1709,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1709,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1722,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1722,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1697,4045368,Cannot tell based on the abstract,, Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1697,4045368,No significant difference,No significant differences were found between the two groups in the severity of the tibial plateau fractures according to the Schatzker (P = 0.556) or AO (P = 0.257) classifications systems (Figures 2 and 3)., Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1689,5362210,Significantly increased,"Significantly more infants with a cerebral burden of hypoxia within the 4th quartile versus infants within quartile 1â3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia.", Burden of hypoxia within the 4th quartile versus quartile 1Ã¢â¬â3 , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1821,5003869,Cannot tell based on the abstract,," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1821,5003869,No significant difference,"For patients starting with RAS-inhibitors 22.6% of the patients in the intervention arm discontinued therapy compared to 27.9% of patients with usual care which is significantly lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-analysis is comparable but not statistically significant. For statins and bisphosphonate users, discontinuation rates were not significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively 0.73, 95% CI 0.56, 1.02)."," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1707,5556332,Cannot tell based on the abstract,, Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1707,5556332,Significantly increased,Surgeons reported more satisfaction with pain control in the medication group in 24 and 48 hours after surgery (P = 0.001) (Table 2)., Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1704,5556332,Significantly decreased,"Patients in the PAN group had significantly lower UPAT scores at 0, 2, 4, 6, 12, 24 and 48 hours after the surgery than those in the control group (P = 0.008, 0.021, 0.008, 0.047, 0.004, 0.001, and 0.001).", UPAT scores , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1817,5003869,Cannot tell based on the abstract,, Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1817,5003869,No significant difference,In the overall ITT analysis we found a mean adherence rate (MPRm) of 74.7% (SD 37.5) for intervention patients and 74.5% (SD 37.9) for control patients (see Table 2)., Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1759,4199180,Cannot tell based on the abstract,, Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1759,4199180,No significant difference,The morbidity/complication profiles among the two groups were comparable [Table 2]., Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1720,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1720,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1729,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1729,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1802,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1836,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1836,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1696,4045368,Cannot tell based on the abstract,, Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1696,4045368,No significant difference,"No difference was observed in the duration of follow-up between the locking plate and nonlocking plate groups (10.61 Â± 3.05 months versus 12.95 Â± 2.63 months, P = 0.158).", Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1765,4526979,No significant difference,"With the exception of health service navigation, mean effect sizes from all other heiQ domains showed a positive trend for My Joint Pain users compared to the nonusers, although the differences between groups did not reach statistical significance.", Domains examined for the heiQ , Nonusers , Website users ,0,
edin,1728,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1728,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531)", Subjective well-being , Placebo , Haloperidol ,0,
edin,1841,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1841,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1782,5697397,Significantly increased,Native whey ingestion induced a greater phosphorylation of p70S6K than milk 180Â min after exercise (Pâ=â0.03)., Phosphorylation of p70S6K 3 hours after exercise , Milk protein  , Native whey protein ,0,
edin,1813,5003869,Cannot tell based on the abstract,"Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1813,5003869,No significant difference,"The mean adherence rate in patients in the intervention arm starting with RAS-inhibitors was 84.1% (SD 31.6) compared to 78.5% (SD 36.6) in the usual care arm which is a significant improvement with a adherence difference based on mixed-effect models of 5.16% (95% CI 1.17, 10.03) (See,In statin users, patients in the intervention arm had a mean adherence rate of 80.5% (32.4) compared to 75.1% (36.8) in the usual care arm, which is a non-significant adherence difference of 4.08% (95% CI â0.81, 6.62).,n patients starting with bisphosphonates, the mean adherence rate in intervention arm (75.2%) was not different from the usual care arm (73.3%) neither was the proportion of adherent patients (70.2% respectively 67.1%)."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1780,4137650,Significantly decreased,The rise in HR (P = 0.08481) and rate pressure product (P = 0.0666) at the time of intubation were minimal and was statistically significant up to 15 min in Group D., Mean rate pressure product up to 15 min after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1718,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1718,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1705,5556332,Significantly decreased,The mean dose of postoperative morphine consumption in the PAN group was 37% less than the control group (P = 0.001)., Consumption of morphine after the surgery , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1755,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1755,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1756,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1711,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1837,5599918,Significantly decreased,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.", Pain intensity after surgery , Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1834,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1786,4878364,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007),", Gait speed , No exercise , Exercise program ,0,
edin,1778,4137650,Significantly increased,The mean arterial pressure was significantly increased in patients receiving placebo (P < 0.0001) and esmolol (P < 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294). T, Mean systolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1792,3798206,Significantly increased,"In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1.30, 95% confidence interval [CI] 0.96â1.76 for dabigatran 110 mg twice daily and OR 1.42, 95% CI 1.07â1.88 for dabigatran 150 mg twice daily).", Rates of myocardial infarction  , Warfarin , Dabigatran ,0,
edin,1814,5003869,Cannot tell based on the abstract,, Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1814,5003869,No significant difference,"For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9).", Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1808,111193,Cannot tell based on the abstract,, Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1808,111193,No significant difference,Fifty percent in the ANH group received homologous blood transfusion during the hospital stay (771 mL pr. patient transfused) vs. 42 % in non-ANH group (800 mL pr. patient transfused) (ns)., Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1763,4526979,No significant difference,"Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs â6%, P=.03) measured on the OAQI."," Self-management as measured on the OAQI, after 12 months ", Nonusers , Website users ,0,
edin,1822,3388481,Significantly increased,In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful ECV procedure than NLP (P = 0.05) and hypnosis and NLP (P = 0.03)., Success of external cephalic version (ECV) procedure , Standard medical care alone , Hypnosis and Neurolinguistic Programming (NLP) ,0,
edin,1826,4733710,Cannot tell based on the abstract,, Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1826,4733710,No significant difference,"Peri-operative Transfusion Trigger Score of Emergency group and control group were compared in age, gender, body mass index, ASA score, and operation area; Heart rate, mean arterial pressure, SpO2, body temperature, and shock index when entering into the operation room; there was no statistical difference between the two groups for Hb values and APACHE II scores after entering into the operation room,Table 4
The two groups of patients are compared in vital signs and Hb (mean Â± SD)", Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1831,2967098,No significant difference,Comparison of the improvement rate in both study groups revealed no significant difference., Improvement rate , Low dose (5 mg/day) haloperidol , High dose (20 mg/day) haloperidol ,0,
edin,1767,4780150,No significant difference,"fter intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Total body stores of vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1768,4780150,No significant difference,"After intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Vitamin A concentrations in the liver , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1757,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1757,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1805,111193,Cannot tell based on the abstract,, Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1805,111193,No significant difference,Time used for anaesthesia (from patient enters the operating theatre to entering the recovery room) and duration of surgery was identical between groups., Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1779,4137650,Cannot tell based on the abstract,, Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1779,4137650,Significantly increased,The DAP levels in Group D were significantly lower than Groups C and E at all times after intubation., Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
